Enantioselective synthesis of BE ring analogues of methyllycaconitine

Article abstract of DOI:10.1016/j.tet.2015.11.057

The enantioselective synthesis of decahydroquinolines mimicking the BE rings of methyllycaconitine (MLA) is reported. The analogues were synthesised via a one-pot cyclisation using ethyl α-(bromomethyl)acrylate, (R)-1-phenylethanamine and cyclohexanone to

Full text of DOI:10.1016/j.tet.2015.11.057

Accepted Manuscript
Enantioselective synthesis of BE ring analogues of methyllycaconitine
Emma Dickson, Lisa I. Pilkington, Margaret A. Brimble, David Barker
PII:
S0040-4020(15)30241-6
10.1016/j.tet.2015.11.057
TET 27314
DOI:
Reference:
To appear in: Tetrahedron
Received Date: 27 August 2015
Revised Date: 10 November 2015
Accepted Date: 24 November 2015
Please cite this article as: Dickson E, Pilkington LI, Brimble MA, Barker D, Enantioselective synthesis of
BE ring analogues of methyllycaconitine, Tetrahedron (2015), doi: 10.1016/j.tet.2015.11.057.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.

Graphical Abstract
ACCEPTED MANUSCRIPT
Enantioselective synthesis of BE ring analogues of methyllycaconitine
Emma Dickson, Lisa I. Pilkington, Margaret A. Brimble* and David Barker*
School of Chemical Sciences, University of Auckland, 23 Symonds St, Auckland, New Zealand
OMe
O
O
O
OMe
C
B
N
D
O
A
NE
H
H
O
F
OH
OH
O
B
E
N
O
H
( )n
O
N
OMe
H
O
R
methyllycaconitine
BE ring analogues

Enantioselective synthesis of BE ring analogues of methyllycaconitine
ACCEPTED MANUSCRIPT
Emma Dickson, Lisa I. Pilkington, Margaret A. Brimble* and David Barker*
School of Chemical Sciences, University of Auckland, 23 Symonds St, Auckland, New Zealand
Corresponding authors. Tel.: +64-9-373-7599; fax: +64-64-373-7422;
E-mail: d.barker@auckland.ac.nz; m.brimble@auckland.ac.nz
Abstract: The enantioselective synthesis of decahydroquinolines mimicking the BE rings of methyllycacontine
(MLA) is reported. The analogues were synthesised via one-pot cyclisation using ethyl α-
a
(bromomethyl)acrylate, (R)-1-phenylethanamine and cyclohexanone to form chiral octahydroquinolines which
can be selectively hydrogenated to form the 3-substituted-decahydroquinolines with the same stereochemistry
found in MLA. The amine and ketone components in the one-pot reaction can also be altered to provide access
to structurally related heterocycles.
Key words: Multi-component reaction; quinolones; methyllycaconitine; enantioselective synthesis
1. Introduction
Methyllycaconitine (MLA) 1, first discovered by Manske in 1938,1 is the 2-[2-(S)-methylsuccinimido]benzoate
ester of the norditerpenoid alkaloid lycoctonine 2 and is the major toxic component in Delphinium brownii.2 An
essential structural feature of MLA 1, this N-substituted anthranilate ester is postulated to be a key
pharmacophore in the molecule.2,3 It has been proposed that at physiological pH the tertiary amine in the E ring
system of MLA 1 is protonated and together with the ester form a homocholine motif which mimics
acetylcholine.2 It is also predicted that the methylsuccinimido moiety may help to maintain the correct geometry
between the tertiary nitrogen atom of the piperidine E ring in the alkaloid with the carbonyl oxygen of the ester
bond.4
OMe
O
OMe
C
B
D
A
NE
F
OH
OH
H
R
OMe
O
O
O
N
methyllycaconitine (1) R =
lycoctonine (2) R = H
O
Figure 1. Methyllycaconitine 1 and lycoctonine 2
The primary mode of action of methyllycaconitine 1 is through competitive blockade at the nicotinic
acetylcholine receptors (nAChRs) and whilst methyllycaconitine binds to all subtypes of nAChRs it has high
affinity to the α7 nAChR subtype. The α7 nAChR subtype is amongst the most common in the brain and has
been linked to pain, neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease as well as
psychiatric disorders such as schizophrenia and depression.5 MLA 1 is one of only a handful of compounds,
which also include the poison frog alkaloid 235B6 and the peptide toxins α-bungarotoxin and α-conotoxin ImI,
that bind with high affinity and selectivity to the α7 nAChR.7 Additionally, methyllycaconitine 1 is reported to
be one of the most potent, non-protein, competitive α7 nAChR antagonists presently available.
Structure–activity relationship studies on MLA 1 have shown that the N-substituted anthranilate ester moiety is
essential for potent pharmacological activity.2 This can be seen through comparison of the neuronal activity of
MLA 1 and lycoctonine 2; it has been established that lycoctonine 2, which does not contain this structural
feature, exhibits 2000 times less affinity for rat neuronal α7 nAChRs than MLA 1 (Figure 1).2 Similarly,
removal of the N-ethyl group in the E ring results in a greater than 10-fold reduction in potency.8 Of additional
1

note, a structure–activity relationship study of simple E ring analogues by Bergmeier et al.9 demonstrated that
ACCEPTED MANUSCRIPT
the N-3-phenylpropyl moiety in comparison to the natural N-Et group resulted in a significant increase in
binding affinity.
In the hexacyclic core structure of methyllycaconitine 1 the key piperidine E ring is embedded within an azabi-
cyclo[3.3.1]nonane and a decahydroquinoline, forming the AE and BE ring systems respectively. Many
groups,9,10,11 including our own,10 have synthesised analogues of these alkaloids and most previous syntheses
have focused on constructing azabicyclo[3.3.1]nonanes10,11 to mimic the AE rings, whilst others have worked
specifically on the synthesis of piperidine E-ring analogues 2 (Figure 1). There are, however, only two reported
examples of BE ring analogues, both of which were racemic analogues and only in one was the
pharmacologically important anthranilate ester moiety introduced.12
We have previously reported12 the synthesis of racemic BE ring analogues using a one-pot bicyclization reaction
of cyclohexanone and non-volatile amines to form the core octahydroquinoline. We now herein report the
enantioselective synthesis of the decahydroquinoline BE rings of methyllycaconitine as well as a number of
bicyclic analogues of the BE ring system.
2. Results and Discussion
Our synthetic strategy to the bicyclic compounds utilizes a one-pot reaction involving, a primary amine, ethyl
α-(bromomethyl)acrylate 3 and a cyclic ketone and is based on a method first reported by Hori et al. for the
synthesis of ergot alkaloids.13 We previously demonstrated the method could be applied using cyclohexanone 4a
and non-volatile amines to afford octahydroquinolines in good yields. All previous examples of this
condensation utilized a cyclohexanone12,13 as the ketone component, therefore we first wished to determine
whether other cyclic ketones could be used to provide alternative heterocyclic systems. 3,5-cis-
Dimethylcyclohexanone 4b was prepared from the hydrogenation of 3,5-dimethyl-2-cyclohexen-1-one,14 whilst
commercially available cyclohexanone 4a, cycloheptanone 4c and cyclopentanone 4d were also chosen. Ethyl
α-(bromomethyl)acrylate 3 was prepared from ethyl acrylate using literature methods.15 Ketones 4a-d were then
reacted with acrylate 3 and benzylamine 5a and gave bicycles 6a-c in similar 70-76% yields (Table 1, entries 1-
3). The 5/6-fused bicycle 6d formed from cyclopentanone 4d and benzylamine 5a was obtained in only 13%
yield (Table 1, entry 4). To expand our study we then tested the reaction with alternative primary amines, 3-
phenylpropylamine 5b and chiral amine (R)-α-methyl benzylamine 5c, again using ketones 4a-d (Table 1,
entries 5-12). The yields of the bicyclic compounds 6e-j were similar to those produced using benzylamine 5a,
with reactions involving cyclopentanone 4d again giving bicycles 6k,l in lower yields. Bicycles 6f,h,j,l were
obtained as single diastereomers, which were later determined to have an S configuration at C-3 (see below).
The lower yields of the 5/6-fused bicyles 6d,k,l are presumably due to the unfavourable formation of this more
strained ring system. Due to the fact that these compounds 6d,k,l were obtained in low yields and were found to
be unstable even when stored at low temperatures, only the elaboration of bicycles 6a-c,e-j was pursued.
Bicycles 6b,g,h were obtained as single diastereomers with NOESY correlations between H-5 and H-7
indicating the methyl groups at these positions were syn. However, the relative stereochemistry between H-3
and H-5/7 could not be determined.
With bicycles 6a-c,e-j mimicking the BE rings of methyllycaonitine in hand, we turned to the hydrogenation of
the tetrasubstituted alkene to obtain the cis stereochemistry which is found in ring systems of MLA 1. Bicycles
6a-c,e-j were hydrogenated (1 atm.) over Adam’s catalyst (PtO2)13 in ethyl acetate for 18 h to afford the
corresponding saturated bicycles 7a-i (Scheme 1). Purification of the bicycles was performed using basic
alumina, as significant loss of product was found when silica gel was used. Hydrogenation of the unsubstituted
octahydroquinolines 6a,e,f gave decahydroquinolines 7a-c in 41–72% yield, while hydrogenation of the 6/7-
fused bicycles 6c,i,j and dimethyl-substituted octahydroquinolines 6b,g,h gave saturated bicycles 7d-h in
generally lower yields, whilst 7i was not formed and only a complex mixture obtained. In all cases only the cis-
syn stereochemistry was obtained, as confirmed by the observation of NOESY correlations between 4a-H and
both 8a-H (9a-H in the case of 7d-f) and 3-H, thus establishing the relative stereochemistry to be the same as
that found in MLA 1 (Figure 2). The stereochemistry was further confirmed when a subsequent derivative was
found to be suitable for X-ray crystallographic analysis (see below). Decahydroquinolines 7g and 7h were
isolated as single diastereomers where the relationship between H-5/7 and H-3/4a/8a could not be determined
thus 7g and 7h are either the 3S*,4aS*,5R*,7S*,8aR* or 3S*,4aS*,5S*,7R*,8aR* diastereomers.
2

Table 1: Synthesis of bicyclic aminoesters 6 and 7
ACCEPTED MANUSCRIPT
CO2Et
4aH
H
Br
H2
PtO2
CO2Et
CO2Et
3
O
3
R NH2
+
( )
( )
N
N
toluene
relfux
H
( )n
EtOAc
8/9a
R
R
n = 1,2,3
4
5
6
7
Entry
1
Ketone
Amine
Bicycle 6 (Yield %)
Bicycle 7 (Yield %)
H
CO2Et
CO2Et
O
Ph
NH2
N
6a (70%)
N
7a (54%)
4a
5a
H
CH2Ph
CH2Ph
H
4
5
CO2Et
CO2Et
O
6
4a
3
8a
2
5a
2
N
N1
6b (76%)*
CH2Ph
CO2Et
cis-4b
7
7g (42%)*
CH2Ph
H
8
H
H
CO2Et
7d (58%)
O
O
3
4
5
5a
5a
N
6c (75%)
CH2Ph
CO2Et
N
4c
CH2Ph
NA
N
6d (13%)
CH2Ph
CO2Et
4d
H
H
CO2Et
Ph
NH2
4a
N
6e (60%)
(CH2)3Ph
CO2Et
N
7b (41%)
5b
(CH2)3Ph
H
H
CO2Et
Ph NH2
6
7
4a
4b
4b
4c
4c
6f (84%)
N
7c (72%)
N
5c
Ph
Ph
H
4
5
4a
8a
CO2Et
CO2Et
6
3
2
5b
5c
5b
5c
7h (43%)*
N1
N
7
6g
(43%)*
(CH2)3Ph
H
8
(CH2)3Ph
CO2Et
8
7i Complex mixture
6h (30%)*
Ph
CO2Et
6i
N
N
H
CO2Et
9
(62%)
7e
(54%)
N
H
(CH2)3Ph
CO2Et
6j (64%)
(CH2)3Ph
H
CO2Et
7f (52%)
10
N
N
H
Ph
CO2Et
6k
Ph
11
12
NA
NA
4d
4d
5b
5c
(17%)
N
(CH2)3Ph
CO2Et
6l (14%)
N
Ph
NA = not attempted. * The relationship between the syn 5/7-dimethyl groups and H-3 could not be determined.
3

4aH
H
CO2Et
ACCEPTED MANUSCRIPT
H4a
3
H3
H8a
( )n
N
R
N
R
H
7
CO2Et
( )n
8a
Figure 2. Relative stereochemistry of saturated bicycles 7 determined by nOe interactions between H-3, H-4a
and H-8a.
With the saturated bicycles mimicking the BE rings of MLA now formed, the addition of the 2-(2-
methylsuccinimido)benzoate ester was required (Scheme 1, Table 2). This was achieved by reduction of the
ethyl esters 7a-h using LiAlH4 in THF to afford alcohols 8a-h in quantitative yield. After purification, alcohol
8c bearing the chiral (R)-α-methyl benzylamine moiety was obtained as a crystalline solid suitable for X-ray
crystallographic analysis (Figure 3). The X-ray crystal structure confirmed the stereochemistry between H-4a,
H-8a and H-3 and established the absolute stereochemistry of the bicycle to be 3S,4aR,8aR, which is the same as
that found in MLA 1. The final steps were to install the succinimido anthranilate ester pharmacophore of MLA
1. This was achieved firstly by the DCC (2 equiv.), DMAP (0.1 equiv.) mediated coupling of 2-(3-methyl-2,5-
dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoic acid 916 (2.0 equiv.) with alcohols 8a-h, in CH2Cl2, and afforded
anthranilate esters 10a-h in 53–95% yields. Finally the maleimide unit in anthranilates 10a-h was hydrogenated
over 10% palladium on charcoal (1 atm.) for 18 h to yield the desired succinimido anthranilates 11a-h in near
quantitative yields. This reaction gave succinimido anthranilates 11a-h as 1:1 mixtures of diastereomers at the
C-3′′ position. Preparation of enantiopure succinimido anthranilates has previously been achieved via the three
step process10q,16 however biological assessment has shown diastereomeric mixtures have similar activity to
single isomers.9h,10l
DCC,
DMAP
CH2Cl2
LiAlH4,
THF
4aH
( )n
H
4a H
( )n
H
CO2Et
O
OH
3
3
O
N
HOOC
+
N
R
N
R
r.t., 18 h
H
H
r.t., 15 min
quant.
8/9a
8/9a
−
53 95%
7
8
9
3''
O
O
O
O
H2 (1 atm),
Pd/C (10 mol%).
EtOAc
N
N
O
O
4aH
( )n
H
4aH
H
O
O
3
3
( )n
N
R
18 h
N
R
H
H
−
8/9a
8/9a
95 99%
10
11
Scheme 1. Synthesis of succinimido anthranilates 11.
4

ACCEPTED MANUSCRIPT
Table 2: Synthesis of succinimido anthranilates 11.
Bicycles 7/8
Anthranilate ester 10
Succinimido anthranilate 11
Yield from 7
(R = CO2Et, 7; R = CH2OH, 8)
(three steps)
O
O
H
R
O
N
O
N
O
O
O
O
O
H
H
H
H
O
O
O
51%
90%
7a/8a
N
H
N
N
CH2Ph
CH2Ph
11a
CH2Ph
10a
O
O
O
O
H
H
N
N
R
H
H
H
H
O
N
7b/8b
N
N
(CH2)3Ph
(CH2)3Ph
11b
(CH2)3Ph
10b
O
O
O
O
H
H
N
N
R
O
H
H
H
H
O
O
67%
76%
7c/8c
N
N
N
N
Ph
Ph
10c
Ph
11c
O
O
O
O
H
H
N
N
R
O
O
H
H
O
O
7d/8d
N
N
CH2Ph
H
H
CH2Ph
11d
CH2Ph
10d
O
O
O
O
H
N
N
R
O
O
O
O
H
H
H
H
O
O
63%
87%
7e/8e
N
H
N
N
(CH2)3Ph
11e
(CH2)3Ph
10e
(CH2)3Ph
O
O
O
O
H
H
N
N
R
H
H
H
H
O
O
7f/8f
N
N
N
N
Ph
10f
11f
Ph
Ph
O
O
O
O
H
H
N
N
R
O
O
H
H
O
O
O
O
68%
76%
7g/8g
N
N
H
H
CH2Ph
CH2Ph
11g
CH2Ph
10g
O
O
O
O
H
H
N
N
R
O
O
H
H
H
H
7h/8h
(CH2)3Ph
N
N
(CH2)3Ph
N
(CH2)3Ph
11h
10h
5

ACCEPTED MANUSCRIPT
Figure 3. X-ray crystal structure of 8c (available from the CCDC: 1419766).
H
CO2Et
H
Ac2O, DMAP
CH2Cl2/Et3N (1:1)
H
H
H
H
LiAlH4,
THF
10% Pd/C.
H2, MeOH
CO2Et
CO2Et
OH
N
H
N
N
18 h
91%
N
0 °C to r.t.
20 h, quant.
H
O
0 °C to r.t.
23 h, quant.
H
7c
12
13
14
O
O
O
N
O
O
N
O
Pd/C (10 mol%),
H2 (1 atm), EtOAc
9, DCC,
DMAP
H
H
H
O
O
18 h
99%
r.t., 18 h
80%
N
N
H
16
15
Scheme 2. Synthesis of succinimide anthranilate 16.
The decahydroquinoline BE rings of MLA 1 have an N-ethyl group and we envisaged that this could be
introduced by hydrogenolysis of the (R)-α-methyl benzylamine moiety in 7c and subsequent addition of an ethyl
moiety. Whilst the α-methyl benzylamine group had not been removed upon hydrogenation over PtO2 we found
that hydrogenation of 7c over 10% palladium on charcoal (1 atm.) in MeOH for 18 h gave amine 12 in 91%
yield (Scheme 2). Amine 12 was reacted immediately with acetic anhydride and DMAP in CH2Cl2/Et3N (1:1) to
allow acetamide 13 in quantitative yield. Acetamide 13 underwent complete degradation when subjected to
chromatography with either silica or alumina and was therefore reduced immediately, using LiAlH4, to give
amino alcohol 14 in quantitative yield. Coupling of alcohol 14 with acid 9 followed by hydrogenation of the
resultant maleimide 15 gave succinimido anthranilate 16 in 79% yield over two steps. Anthranilate 16 contains
the complete carbon framework of the BE rings of MLA 1 including the natural N-ethyl substituent, with the
same absolute stereochemistry as the natural product.
3. Conclusions
In conclusion we have reported the use of a three component, one-pot, cyclisation reaction to form 2,3-fused
5/6, 6/6 and 7/6 piperidine heterocycles. Subsequent transformation of the bicycles into analogues of the BE
rings of MLA 1 has also been achieved. Use of a chiral (R)-α-methyl benzylamine auxiliary allowed the
synthesis of enantiopure decahydroquinoline 7c which was converted into succinimido anthranilate 16 in 72%
yield in 5 steps. This synthesis of anthranilate 16 constitutes the first asymmetric synthesis of the complete
carbon framework of the BE rings of methyllycaconitine 1.
4. Experimental Section
4.1 General Experimental
Analytical thin layer chromatography (TLC) was performed using 0.2 mm thick precoated silica gel plates
(Merck Kieselgel 60 F254). Compounds were visualized by ultraviolet fluorescence or by staining iodine. Flash
chromatography was performed using Riedel-de Haën silica gel (0.032-0.063 mm) with the indicated solvents.
1H NMR spectra were recorded with a Bruker DRX 300 (300 MHz) or a Bruker DRX 400 (400 MHz)
6

spectrometer at ambient temperature using CDCl3 as a solvent. Chemical shifts are given in parts per million
ACCEPTED MANUSCRIPT
(ppm) downfield shift from tetramethylsilane as an internal standard, and reported as position (δ), multiplicity (s
= singlet, d = doublet, dd = double of doublets, ddd = doublet of doublet of doublets, ddt = doublet of doublet of
triplets, dt = doublet of triplets, m = multiplet, t = triplet, td = triplet of doublets, q = quartet), relative integral,
assignment and coupling constant (J in Hz). 13C NMR spectra were recorded with a Bruker DRX 300 (75 MHz)
or a Bruker DRX 400 (100 MHz) spectrometer at ambient temperature with complete proton decoupling.
Chemical shifts are expressed in parts per million referenced to the residual chloroform peak (δ = 77.0 ppm),
and reported as position (δ) and assignment, aided by DEPT 135 experiments. In addition, 1H-1H-COSY, 1H-1H-
NOESY and 1H-13C-HSQC correlation spectra were used for the complete assignment of the proton and carbon
resonances. High resolution mass spectra were recorded with a VG-70SE mass spectrometer. Ionisation method
employed was electron impact (EI) or electrospray ionization (ESI). Melting points were determined on a Kofler
20
hot-stage apparatus and are uncorrected. [α]D values are given in 10–1 deg cm3 g–1. Ethyl 2-
(bromomethyl)acrylate 315 and 2-(3-methyl-2,5-dioxo-2,5-dihydropyrrol-1-yl)benzoic acid 916 were prepared as
reported. X-ray crystal structures were obtained using a Bruker SMART platform goniometer with a CCD area
detector at 150 K with structural solution and refinement by SHELXTL software package.
4.1.1 3,5-cis-Dimethylcyclohexanone 4b. To a solution of 3,5-dimethyl-2-cyclohexeneone (0.400 g, 3.22 mmol)
in isopropanol (4.0 mL) was added 10% palladium on carbon (0.04g, 0.38 mmol) and the resulting mixture was
stirred under an atmosphere of hydrogen for 2 h. The mixture was filtered through Celite and washed with
further isopropanol (20 mL) and the solvent was removed in vacuo to give the title compound 4b (0.406 g,
1
100%) as a pale blue/green oil that was used immediately without further purification; H NMR (400 MHz;
CDCl3): δ = 1.02 (6H, d, J = 5.8 Hz, 3-CH3 and 5-CH3), 1.78-1.97 (4H, m, H-3, H-4, H-5), 2.33 (4H, d, J = 11.8
Hz, H-2 and H-6). 13C NMR (100 MHz, CDCl3) 22.3 (3-CH3 and 5-CH3), 33.2 (C-3 and C-5), 42.8 (C-4), 49.2
(2 x CH2, C-2 and C-6), 212.11 (q, COO). The spectroscopic data was consistent with literature values.14
4.2 General Method A: Three component synthesis of bicycles 6. To amine 5 (6.0 mmol) in toluene (32 mL)
was added dropwise ethyl 2-(bromomethyl)acrylate 3 (3.00 mmol) in toluene (5 mL) at 0 °C. After 15 min a
solution of cyclic ketone 4 (3.00 mmol) in toluene (5 mL) was added and the reaction mixture was heated under
reflux under N2 for 18 h using a Dean-Stark trap containing 5 Å molecular sieves. The mixture was cooled and
extracted with 1 M HCl (2 × 100 mL). The combined aqueous layers were washed with ethyl acetate (100 mL),
basified with solid Na2CO3 and then extracted with CH2Cl2 (3 × 75 mL). The extract was dried Na2SO4 and
concentrated in vacuo. The crude product was purified by column chromatography using silica gel to give the
desired unsaturated bicycle 6.
4.2.1 Ethyl 1-benzyl-1,2,3,4,5,6,7,8-octahydroquinoline-3-carboxylate 6a. Using general method A, benzyl
amine 5a (0.655 mL, 6.0 mmol) and cyclohexanone 4a (0.310 mL, 3.0 mmol) after purification by flash
chromatography (20% ethyl acetate in n-hexanes) gave the title compound 6a (0.632 g, 70%) as a bright yellow
oil; RF = 0.68 (4:1 n-hexanes, ethyl acetate); νmax/cm-1 3025, 2927, 2836, 1727, 1176, 1027; 1H NMR (300 MHz;
CDCl3): δ = 1.21 (3H, t, J = 7.0 Hz, OCH2CH3), 1.55-1.73 (4H, m, H-6 and H-7), 1.81-2.14 (3H, m, H-5 and
HA-8), 2.15-2.26 (3H, m, H-4 and HB-8), 2.61-2.75 (1H, m, H-3), 2.91 (1H, t, J = 11.3 Hz, HA-2), 3.14 (1H,
ddd, J = 1.9, 3.3, 11.3 Hz, HB-2), 3.96-4.06 (2H, m, NCH2Ph), 4.07-4.13 (2H, m, OCH2CH3), 7.22-7.33 (5H, m,
Ar-H); 13C NMR (75.5 MHz; CDCl3): δ = 14.14 (OCH2CH3), 23.0 (C-7), 23.6 (C-6), 26.7 (C-5), 29.9 (C-8),
31.2 (C-4), 37.6 (C-3), 50.0 (C-2), 53.8 (NCH2Ph), 60.2 (OCH2CH3), 106.3 (C-4a), 126.7 (Ar-CH), 127.6 (Ar-
CH), 128.19 (Ar-CH), 135.9 (q, C-8a), 140.12 (Ar-C) and 174.5 (q, COO); MS (EI): m/z = 299 (M+, 76%), 226
(25), 208 (75), 91 (100); HRMS (EI): C19H25NO2 requires 299.18853; found: 299.18823.
4.2.2 Ethyl 1-benzyl-5,7-dimethyl-1,2,3,4,5,6,7,8-octahydroquinoline-3-carboxylate 6b. Using general method
A, benzylamine 5a (0.568 mL, 5.2 mmol) and 3,5-cis-dimethylcyclohexanone 4b (0.372 mL, 2.6 mmol) after
purification by flash chromatography (20% ethyl acetate in n-hexanes) gave the title compound 6b (0.605 g,
76%) as a pale yellow oil. RF = 0.75 (4:1 n-hexanes, ethyl acetate); νmax/cm-1 3019, 2951, 2907, 1729, 1453,
1171, 1028; 1H NMR (400 MHz; CDCl3): δ = 0.80-0.92 (1H, m, HA-6), 0.96 (3H, d, J = 6.2 Hz, 5-CHCH3), 1.00
(3H, d J = 6.6 Hz, 7-CHCH3), 1.22 (3H, t, J = 7.0 Hz, OCH2CH3), 1.61-1.79 (3H, m, H-4 and HB-6), 1.99 (1H,
dd, J = 3.0, 15.8 Hz, HA-8), 2.12-2.25 (2H, m, H-5 and H-7), 2.35 (1H, td, J = 3.0, 13.6 Hz, HB-8), 2.67 (1H,
tdd, J = 2.8, 5.2 and 11.3 Hz, H-3), 2.78 (1H, t, J = 11.3 Hz, HA-2), 3.13 (1H, dt, J = 2.8, 11.3 Hz, HB-2), 3.95-
4.02 (1H, m, NCHAHBPh), 4.05-4.13 (2H, m, CO2CH2CH3), 4.14-4.27 (1H, m, NCHAHBPh) and 7.20-7.36 (5H,
7

m, Ar-H); 13C NMR (100 MHz, CDCl3): δ = 14.2 (OCH2CH3), 20.5 (7-CHCH3), 22.2 (5-CHCH3), 29.2 (C-8),
ACCEPTED MANUSCRIPT
35.2 (C-5 and C-7), 35.7 (C-4), 38.3 (C-3), 41.6 (C-6), 49.9 (C-2), 53.9 (NCH2Ph), 60.3 (OCH2CH3), 109.1 (C-
4a), 126.7 (Ar-CH), 127.5 (Ar-CH), 128.3 (Ar-CH), 135.9 (C-8a), 140.1 (Ar-C) and 174.8 (COO); HRMS
(ESI): m/z [MH]+ C21H30NO2 requires 328.2270; found 328.2271.
4.2.3 Ethyl 1-benzyl-2,3,4,5,6,7,8,9-octahydro-1H-cyclohepta[b]pyridine-3-carboxylate 6c. Using general
method A benzylamine 5a (0.568 mL, 5.2 mmol) and cycloheptanone 4c (0.306 mL, 2.6 mmol) after
purification by flash chromatography (33% ethyl acetate in n-hexanes) gave the title compound 6c (0.611g,
75%) as a bright yellow oil. RF = 0.7 (4:1 n-hexanes, ethyl acetate); νmax/cm-1 3063, 3035, 2915, 2843, 1728,
1
1454, 1155; H NMR (400 MHz; CDCl3) δ = 1.21 (3H, t, J = 7.2 Hz, OCH2CH3), 1.30-1.51, 1.54-1.75, 1.76-
1.87 and 2.19-2.43 (10H, 4 x m, H-5, H-6, H-7, H-8 and H-9), 2.02-2.16 (2H, m, H-4), 2.54-2.64 (1H, m, H-3),
2.68-2.79 (1H, m, HA-2), 3.03-3.12 (1H, m, HB-2), 3.55-3.64 (1H, m, NCHACHBPh), 4.03-4.14 (3H, m,
NCHACHBPh and OCH2CH3) and 7.16-7.39 (5H, m, Ar-H); 13C NMR (100 MHz, CDCl3) δ = 14.2 (OCH2CH3),
27.0, 27.6, 32.2, 32.3 and 32.5 (C-5, C-6, C-7, C-8 and C-9), 33.6 (C-4 ), 35.6 (C-3), 49.4 (C-2), 54.4
(NCH2Ph), 60.2 (OCH2CH3), 116.0 (C-4a), 126.9 (Ar-CH), 127.9 (Ar-CH), 128.1 (Ar-CH), 139.9 (q, C-9a),
143.3 (Ar-C), 174.7 (COO); HRMS (ESI): m/z: [MH]+ C20H28NO2 requires 314.2115; found 314.2115.
4.2.4 Ethyl 1-benzyl-2,3,4,5,6,7-hexahydro-1H-cyclopenta[b]pyridine-3-carboxylate 6d. Using general method
A benzylamine 5a (0.568 mL, 5.2 mmol) and cyclopentanone 4d (0.230 mL, 2.6 mmol) after purification by
flash chromatography (66% ethyl acetate in n-hexanes) gave the title compound 6d (0.101 g, 13%) as a brown
oil. RF = 0.65 (4:1 n-hexanes, ethyl acetate); νmax/cm-1 3469, 2934, 2843, 1727, 1452, 1367, 1179; 1H NMR (400
MHz; CDCl3) δ = 1.21 (3H, t, J = 7.5 Hz, OCH2CH3), 1.83-1.94 (2H, m, H-6), 2.17-2.34 (3H, m, H-4, HA-5),
2.37-2.44 (1H, m, HB-5), 2.45-2.53 (2H, m, H-7), 2.70-2.80 (1H, m, H-3), 2.93 (1H, t, J = 11.5 Hz, HA-2), 3.08-
3.15 (1H, m, HB-2), 4.02-4.17 (4H, m, NCH2Ph and OCH2CH3), 7.20-7.39 (5H, m, Ar-H); 13C NMR (100 MHz,
CDCl3) δ = 14.1 (OCH2CH3), 20.8 (C-6), 26.9 (C-4), 31.2 (C-7), 34.0 (C-5), 39.0 (C-3), 49.5 (C-2), 55.6
(NCH2Ph), 60.3 (OCH2CH3), 106.6 (C-4a), 126.8 (Ar-CH). 127.7 (Ar-CH), 128.3 (Ar-CH), 139.3 (Ar-C), 141.8
(C-7a), 174.4 (COO); HRMS (ESI): m/z = [MH+] C18H24NO2 requires 286.1802; found 286.1810.
4.2.5 Ethyl 1-(3-phenylpropyl)-1,2,3,4,5,6,7,8-octahydroquinoline-3-carboxylate 6e. Using general method A 3-
phenylpropylamine 5b (0.854 mL, 6.0 mmol) and cyclohexanone 4a (0.310 mL, 3.0 mmol) after purification by
flash chromatography (20% ethyl acetate in n-hexanes) gave the title compound 6e (0.589 g, 60%) as a pale
yellow oil. RF = 0.8 (4:1 n-hexanes, ethyl acetate); νmax/cm-1 3025, 2925, 2857, 1727, 1496, 1379, 1260, 1176,
1
1026; H NMR (300 MHz; CDCl3) δ = 1.25 (3H, t, J = 6.8 Hz, OCH2CH3), 1.43-1.79 (4H, m, H-6 and H-7),
1.72-1.79 (2H, m, NCH2CH2CH2Ph), 1.82-1.90 (4H, m, H-5 and H-8), 1.97-2.03 (2H, m, H-4), 2.59 (2H, dt, J =
2.7, 8.3 Hz, NCH2CH2CH2Ph), 2.71 (1H, ddt, J = 3.3, 5.7, 11.8 Hz, H-3), 2.86-2.99 (3H, m, HA-2 and
NCH2CH2CH2Ph), 3.20 (1H, ddd, J = 1.8, 3.3, 11.8 Hz, HB-2), 4.15 (2H, m, OCH2CH3), 7.17-7.28 (5H, m, Ar-
H); 13C NMR (75.5 MHz; CDCl3) δ = 14.2 (OCH2CH3), 22.9 (C-7), 23.6 (C-6), 26.4 (NCH2CH2CH2Ph), 29.7
(C-8), 29.9 (C-5), 31.2 (C-4), 33.36 (NCH2CH2CH2Ph), 38.1 (C-3), 50.0 (NCH2CH2CH2Ph), 50.2 (C-2), 60.3
(OCH2CH3), 106.1 (C-4a), 125.7 (Ar-CH), 128.3 (2 x Ar-CH), 135.8 (q, C-8a), 142.0 (Ar-C), 174.6 (COO); MS
(EI): m/z = 327 (M+, 4%), 222 (10), 91 (55); HRMS (EI): C21H29NO2 requires 327.2198; found 327.2197.
4.2.6 (3S)-Ethyl 1-((R)-1-phenylethyl)-1,2,3,4,5,6,7,8-octahydroquinoline-3-carboxylate 6f. Using general
method A, (R)-1-phenylethylamine 5c (0.727 mL, 6.0 mmol) and cyclohexanone 4a (0.310 mL, 3.0 mmol) after
purification by flash chromatography (20% ethyl acetate in n-hexanes) gave the title compound 6f (0.789 g,
20
84%) as a bright yellow oil. [α]D + 39 (c 0.89, CHCl3); RF = 0.70 (4:1 n-hexanes, ethyl acetate); νmax/cm-1
1
3021, 2930, 2846, 1727, 1446, 1371, 1176, 1026; H NMR (300 MHz; CDCl3) δ = 1.94 (3H, t, J = 7.1 Hz,
OCH2CH3), 1.43 (3H, d, J = 7.0 Hz, NCH(CH3)Ph), 1.60-1.77 (4H, m, H-6 and H-7), 1.85-2.08 (3H, m, H-5 and
HA-8), 2.13-2.36 (3H, m, H-4 and HB-8), 2.61-2.70 (2H, m, HA-2 and H-3), 2.98-3.10 (1H, m, HB-2), 3.99-4.17
(2H, m, OCH2CH3), 4.73-4.81 (1H, m, NCH(CH3)Ph), 7.23-7.40 (5H, m, Ar-H); 13C NMR (75 MHz; CDCl3) δ
= 14.1 (OCH2CH3), 15.5 (NCH(CH3)Ph), 23.1 (C-7), 23.9 (C-6), 26.7 (C-5), 30.1 (C-8), 30.3 (C-4), 38.1 (C-3),
44.9 (C-2), 53.3 (NCH(CH3)Ph), 60.1 (OCH2CH3), 105.6 (C-4a), 126.5 (Ar-CH), 127.2 (Ar-CH), 128.6 (Ar-
CH), 134.5 (C-8a), 143.3 (Ar-C), 174.7 (COO); HRMS (ESI): m/z = [M]+ C20H27NO2 requires 313.20418; found
313.20420.
8

4.2.7 Ethyl 5,7-dimethyl-1-(3-phenylpropyl)-1,2,3,4,5,6,7,8-octahydroquinoline-3-carboxylate 6g. Using general
ACCEPTED MANUSCRIPT
method A 3-phenylpropylamine 5b (0.740 mL, 5.2 mmol) and 3,5-cis-dimethylcylohexanone 4b (0.372 mL, 2.6
mmol) after purification by flash chromatography (33% ethyl acetate in n-hexanes) gave the title compound 6g
(0.400 g, 43%) as a pale yellow oil. RF = 0.6 (3:1 n-hexanes, ethyl acetate); νmax/cm-1 3028, 2956, 2925, 1721,
1
1451, 1188, 1028; H NMR (400 MHz; CDCl3) δ = 0.75-0.84 (1H, m, HA-6), 0.92 (3H, d, J = 6.2 Hz, 5-CHC-
H3), 0.95 (3H, d, J = 6.8 Hz, 7-CHCH3), 1.26 (3H, t, J = 7.2 Hz, OCH2CH3), 1.44-1.54 (1H, m, HA-4), 1.50-1.61
(1H, m, H-5), 1.62-1.70 (1H, m, HB-6), 1.66-1.70 (1H, m, HA-8), 1.78-1.87 (1H, m, HB-8), 1.89-1.97 (1H, m,
NCH2CHAHBCH2Ph), 1.98-2.05 (1H, m, HB-4), 2.06-2.14 (1H, m, H-7), 2.25-2.35 (NCH2CHAHBCH2Ph), 2.58
(2H, t, J = 7.7 Hz, NCH2CH2CH2Ph), 2.60-2.70 (1H, m, H-3), 2.84 (1H, t, J = 11.0 Hz, HA-2), 2.91 (2H, t, J =
7.4 Hz, NCH2CH2CH2Ph), 3.22 (1H, dt, J = 2.6, 11.2 Hz, HB-2), 4.07-4.19 (2H, m, OCH2CH3), 7.11-7.31 (5H,
m, Ar-H); 13C NMR (100 MHz, CDCl3) δ = 14.2 (OCH2CH3), 20.4 (7-CHCH3), 22.1 (5-CHCH3), 29.0 and 29.1
(C-5, C-8 and NCH2CH2CH2Ph), 33.2 (NCH2CH2CH2Ph), 35.2 and 35.3 (C-7 and C-4), 38.6 (C-3), 41.4 (C-6),
50.0 (C-2 and NCH2CH2CH2Ph), 60.2 (OCH2CH3), 109.2 (C-4a), 125.6 (Ar-CH), 128.8 (Ar-CH), 128.3 (Ar-
CH), 135.7 (C-8a), 141.9 (Ar-C), 174.8 (COO); HRMS (ESI): m/z = [MH]+ C23H34NO2 requires 356.2584;
found 356.2590.
4.2.8 (3S)-Ethyl 5,7-dimethyl-1-((R)-1-phenylethyl)-1,2,3,4,5,6,7,8-octahydroquinoline-3-carboxylate 6h. Using
general method A (R)-1-phenethylamine 5c (0.670 mL, 5.2 mmol) and 3,5-cis-dimethylcylohexanone 4b (0.372
mL, 2.6 mmol) after purification by flash chromatography (33% ethyl acetate in n-hexanes) gave the title
compound 6h (0.266 g, 30%) as a pale yellow oil. RF = 0.65 (3:1 n-hexanes, ethyl acetate); νmax/cm-1 2906, 2870,
1729, 1448, 1371, 1170; 1H NMR (400 MHz; CDCl3) δ = 0.82-0.92 (1H, m, HA-6), 0.99 (6H, d, J = 6.7 Hz, 5-
CHCH3 and 7-CHCH3), 1.21 (3H, t, J = 7.0 Hz, OCH2CH3), 1.47 (CH3, d, J = 7.4 Hz, NCH(CH3)Ph), 1.65-1.81
(3H, m, H-5, HB-6 and H-7), 1.93-2.00 (1H, m, HA-8), 2.15-2.21 (1H, m, HA-4), 2.23-2.33 (1H, m, HB-8), 2.36-
2.50 (2H, HA-2 and HB-4), 2.55-2.63 (1H, m, H-3), 3.07-3.14 (1H, m, HB-2), 4.03-4.16 (2H, m, OCH2CH3), 4.90
(1H, q, J = 7.4 Hz, NCH(CH3)Ph), 7.19-7.39 (5H, m, Ar-H); 13C NMR (100 MHz, CDCl3) δ = 14.2 (OCH2CH3),
17.0 (NCH(CH3)Ph), 20.7 (7-CHCH3), 22.3 (5-CHCH3), 29.3 (C-5 or C-7), 29.5 (C-8), 35.46 (C-5 or C-7 and
C-4), 39.6 (C-3), 41.5 (C-6), 44.5 (C-2), 53.1 (NCH(CH3)Ph), 60.2 (OCH2CH3), 108.3 (C-4a), 126.5 (Ar-CH),
127.5 (Ar-CH), 128.2 (Ar-CH), 134.8 (C-8a), 142.9 (Ar-C) and 175.1 (COO); HRMS (ESI) m/z = [MH]+
C22H32NO2 requires 342.2428; found 342.2434.
4.2.9 Ethyl 1-(3-phenylpropyl)-2,3,4,5,6,7,8,9-octahydro-1H-cyclohepta[b]pyridine-3-carboxylate 6i. Using
general method A 3-phenylpropylamine 5b (0.740 mL, 5.2 mmol) and cycloheptanone 4c (0.306 mL, 2.6 mmol)
after purification by flash chromatography (20% ethyl acetate in n-hexanes) gave the title compound 6i (0.551
g, 62%) as a yellow oil. RF = 0.5 (2:1 n-hexanes, ethyl acetate); νmax/cm-1 3025, 2919, 2848, 1726, 1453, 1158;
1H NMR (400 MHz; CDCl3) δ = 1.26 (3H, t, J = 7.0 Hz, OCH2CH3), 1.19-1.34, 1.69-1.85, 1.92-2.12 and 2.15-
2.30 (10H, m, H-5, H-6, H-7, H-8 and H-9), 1.47-1.65 (2H, m, NCH2CH2CH2Ph), 2.48-2.85 (8H, m, HA-2, H-3,
H-4, NCH2CH2CH2Ph, NCH2CH2CH2Ph), 3.18-3.24 (1H, m, HB-2), 4.09-4.17 (2H, m, OCH2CH3) and 7.13-
7.31 (5H, m, Ar-H); 13C NMR (100 MHz, CDCl3) δ = 14.2 (OCH2CH3), 26.8 (NCH2CH2CH2Ph), 27.0, 30.8,
31.8, 32.5 and 32.5 (C-5, C-6, C-7, C-8 and C-9), 33.3 and 36.1 (C-4 and NCH2CH2CH2Ph), 36.1 (C-3), 49.6
(C-2), 50.4 (NCH2CH2CH2Ph), 60.3 (OCH2CH3), 115.1 (C-4a), 125.7 (Ar-CH), 128.3 (2xArCH), 142.1 (C-9a),
143.5 (Ar-C), 174.9 (COO); HRMS (ESI): m/z = [MH+] C22H34NO2 requires 344.2584; found 344.2578.
4.2.10 (3S)-Ethyl 1-((R)-1-phenylethyl)-2,3,4,5,6,7,8,9-octahydro-1H-cyclohepta[b]pyridine-3-carboxylate 6j.
Using general method A (R)-1-phenylethylamine 5c (0.670 mL, 5.2 mmol) and cycloheptanone 4c (0.306 mL,
2.6 mmol) after purification by flash chromatography (33% ethyl acetate in n-hexanes) gave the title compound
6j (0.545 g, 64%) as a bright yellow oil. [α]D20 + 41 (c 1.0, CHCl3); RF = 0.6 (3:1 n-hexanes, ethyl acetate);
νmax/cm-1 3007, 2921, 2848, 1726, 1448, 1377, 1178, 1027; 1H NMR (400 MHz; CDCl3) δ = 1.21 (3H, t, J = 6.8
Hz, OCH2CH3), 1.44 (3H, d, J = 6.8 Hz, NCH(CH3)Ph), 1.62-1.79, 2.20-2.24, 2.25-2.33 and 2.38-2.47 (10H, m,
H-5, H-6, H-7, H-8 and H-9), 2.57-2.63 (3H, m, HA-2 and H-3), 3.03-3.07 (1H, m, HB-2), 4.07-4.22 (2H, m,
OCH2CH3), 4.64 (1H, q, J = 7.0 Hz, NCH(CH3)Ph), 7.19-7.48 (5H, m, Ar-H); 13C NMR (100 MHz, CDCl3) δ =
14.1 (OCH2CH3), 15.5 (NCH(CH3)Ph), 26.7, 27.4, 30.8, 32.3 and 32.5 (C-5, C-6, C-7, C-8 and C-9), 33.9 (C-4),
39.1 (C-3), 45.5 (C-2), 54.8 (NCH(CH3)Ph), 60.2 (OCH2CH3), 114.3 (C-4a), 126.5 (Ar-CH), 127.3 (Ar-CH),
128.4 (Ar-CH), 141.4 (C-9a), 143.7 (Ar-C), 175.0 (COO); HRMS (ESI) m/z = [MH]+ C21H30NO2 requires
328.2271; found 328.2278.
9

4.2.11 Ethyl 1-(3-phenylpropyl)-2,3,4,5,6,7-hexahydro-1H-cyclopenta[b]pyridine-3-carboxylate 6k. Using
general method A 3-phenylpropylaAmiCneC5EbP(T0.7E4D0 mML,A5N.2UmSmColR) aInPdTcyclopentanone 4d (0.230 mL, 2.6
mmol) after purification by flash chromatography (50% ethyl acetate in n-hexanes) gave the title compound 6k
(0.132 g, 17%) as a dark brown oil. RF = 0.8 (1:1 n-hexanes, ethyl acetate); νmax/cm-1 3018, 2938, 1727, 1496,
1454, 1397, 1189, 1029; 1H NMR (400 MHz; CDCl3) δ = 1.26 (3H, t, J = 8.0 Hz, OCH2CH3), 1.68-1.94 (4H, m,
6-CH2 and NCH2CH2CH2Ph), 2.20-2.35 (3H, m, HA-7 and NCH2CH2CH2Ph), 2.36-2.46 (3H, m, H-5 and HB-7),
2.64-2.71 (2H, m, NCH2CH2CH2Ph), 2.78-2.93 (1H, m, H-3), 2.96-3.04 (1H, m, HA-2), 3.25-3.32 (1H, m, HB-
2), 4.15-4.28 (2H, m, OCH2CH3) and 7.18-7.39 (5H, m, Ar-H); 13C NMR (100 MHz, CDCl3) δ = 14.2
(OCH2CH3), 20.9 (C-6), 27.0 (C-4), 29.4 (NCH2CH2CH2Ph), 31.0 (C-5), 33.2 (NCH2CH2CH2Ph), 34.0 (C-7),
39.4 (C-3), 49.5 (C-2), 51.3 (NCH2CH2CH2Ph), 60.4 (OCH2CH3), 106.5 (C-4a), 125.8 (Ar-CH), 128.2 (Ar-CH),
128.3 (Ar-CH), 141.1 (C-7a and Ar-C) and 174.6 (COO); HRMS (EI) m/z = [MH]+ C20H28NO2 requires
314.2215; found 314.2112.
4.2.12 (3S)-Ethyl 1-((R)-1-phenylethyl)-2,3,4,5,6,7-hexahydro-1H-cyclopenta[b]pyridine-3-carboxylate 6l.
Using general method A (R)-1-phenylethylamine 5c (0.670 mL, 5.2 mmol) and cyclopentanone 4a (0.230 mL,
2.6 mmol) after purification by flash chromatography (50% ethyl acetate in n-hexanes) gave the title compound
6l (0.11 g, 14%) as a brown oil. [α]D20 +39 (c 1.0, CHCl3); RF = 0.65 (1:1 n-hexanes, ethyl acetate); νmax/cm-1
2955, 1727, 1636, 1449, 1371, 1177, 1027; δH (400 MHz; CDCl3) 1.18 (3H, t, J = 6.7 Hz, OCH2CH3), 1.44 (3H,
d, J = 7.0 Hz, NCH(CH3)Ph), 1.86-1.99 (2H, m, H-6), 2.17-2.27 (2H, m, H-4), 2.28-2.34 (2H, m, H-7), 2.63-
2.71 (1H, m, H-3), 2.72-2.80 (1H, m, HA-2), 2.77-2.86 (2H, m, H-5), 3.08-3.15 (1H, m, HB-2), 4.04-4.17 (2H,
m, OCH2CH3), 4.57-4.65 (1H, m, NCH(CH3)Ph), 7.18-7.52 (5H, m, Ar-H); δC (100 MHz, CDCl3) 14.1
(OCH2CH3), 16.1 (NCH(CH3)Ph), 20.9 (C-6), 27.0 (C-4), 31.4 (C-5), 34.3 (C-7), 39.6 (C-3), 44.5 (C-2), 56.2
(NCH(CH3)Ph), 60.3 (OCH2CH3), 106.5 (C-4a), 126.7 (Ar-CH), 127.3 (Ar-CH), 128.2 (Ar-CH), 141.0 (Ar-C),
142.7 (C-7a), 174.8 (COO); HRMS (EI+) m/z = [MH]+ C19H26NO2 requires 300.1958; found 300.1965.
4.3 General Method B: Hydrogenation of octahydroquinolines 6 to decahydroquinolines 7. To a solution of
octahydroquinoline 6 (1.0 mmol) in ethyl acetate (5.0 mL) was added platinum oxide (0.04 g, 0.17 mmol) and
the resulting mixture was stirred under hydrogen (1 atm) for 18 h. The mixture was filtered through Celite which
was washed with ethyl acetate (20 mL) and the volatile solvents were removed in vacuo to give the crude
product which was purified by chromatography on basic alumina to give the desired decahydroquinoline 7.
4.3.1 (3S*,4aR*,8aR*)-Ethyl 1-benzyldecahydroquinoline-3-carboxylate 7a. Using general method
B
octahydroquinline 6a (0.415 g, 1.4 mmol) after purification by chromatography on basic alumina (2% ethyl
acetate in n-hexanes) gave title compound 7a (0.227 g, 54%) as a pale yellow oil. RF = 0.70 (4:1 n-hexanes,
ethyl acetate); νmax/cm-1 2927, 2836, 1727, 1660, 1176, 1027; δH (300 MHz; CDCl3) 1.08-1.14 (1H, m, HA-8),
1.21 (3H, t, J = 10.3 Hz, OCH2CH3), 1.31-1.39 (2H, m, H-6), 1.45-1.71 (5H, m, HA-4, H-5, H-7), 1.72-1.92 (2H,
m, HB-4, HB-8), 1.94-2.10 (1H, m, H-4a), 2.51-2.66 (2H, m, HA-2, H-3), 2.67-2.80 (2H, m, HB-2, H-8a), 3.57-
3.62 (1H, m, NCHACHBPh), 3.71-3.76 (1H, m, NCHACHBPh), 4.10 (2H, q, J = 7.0 Hz, OCH2CH3) 7.16-7.31
(5H, m, Ar-H); δC (75.5 MHz; CDCl3) 14.2 (OCH2CH3), 18.1 (C-7), 21.0 (C-6), 25.5 (C-8), 27.3 (C-4), 31.4 (C-
5), 34.7 (C-4a), 42.3 (C-3), 47.0 (C-2), 58.4 (NCH2Ph), 58.9 (C-8a), 60.1 (OCH2CH3), 126.7 (Ar-CH), 128.1
(Ar-CH), 128.4 (Ar-CH), 139.8 (Ar-C), 174.7 (COO); HRMS (EI+) m/z = [M]+ C19H27NO2 requires 301.20418;
found 301.20339.
4.3.2 (3S*,4aR*,8aR*)-Ethyl 1-(3-phenylpropyl)decahydroquinoline-3-carboxylate 7b. Using general method B
octahydroquinline 6e (0.350 g, 1.07 mmol) after purification by chromatography on basic alumina (2% ethyl
acetate in n-hexanes) gave title compound 7b (0.149 g, 41%) as a pale yellow oil. RF = 0.75 (4:1 n-hexanes,
ethyl acetate); νmax/cm-1 2928, 2861, 1727, 1451, 1369, 1247, 1155, 1031; δH (300 MHz; CDCl3) 1.10-1.97 (1H,
m, HA-8), 1.20 (3H, t, J = 7.1 Hz, OCH2CH3), 1.28-1.41 (2H, m, H-6), 1.43-1.50 (2H, m, H-7), 1.51-1.58 (2H,
m, H-5), 1.61-1.73 (2H, m, H-4), 1.74-1.76 (1H, m, HB-8), 1.79-1.87 (2H, m, NCH2CH2CH2Ph), 1.94-2.01 (1H,
m, H-4a), 2.45-2.53 (3H, m, HA-2, NCH2CH2CH2Ph), 2.65 (2H, t, J = 7.6 Hz, NCH2CH2CH2Ph), 2.55-2.67 (1H,
m, H-3), 2.68-2.73 (1H, m, H-8a), 2.78 (1H, dd, J = 2.7, 11.2 Hz, HB-2), 4.11 (2H, q, J = 7.1 Hz, OCH2CH3)
7.14-7.29 (5H, m, Ar-H); δC (75.5 MHz; CDCl3) 14.0 (OCH2CH3), 17.3 (C-7), 20.2 (C-6), 25.3 (C-8), 26.9 (C-
4), 29.3 (NCH2CH2CH2Ph), 31.2 (C-5), 33.4 (NCH2CH2CH2Ph), 34.5 (C-4a), 42.0 (C-3), 47.2 (C-2), 53.1
(NCH2CH2CH2Ph), 58.4 (C-8a), 59.9 (OCH2CH3), 125.4 (Ar-CH), 128.0 (Ar-CH), 128.1 (Ar-CH), 142.1 (Ar-
C), 174.2 (COO); HRMS (EI+) m/z = [M]+ C21H31NO2 requires 329.2355, found 329.2353.
10

4.3.3 (3S,4aR,8aR)-Ethyl 1-((R)-1-phenylethyl)decahydroquinoline-3-carboxylate 7c. Using general method B
ACCEPTED MANUSCRIPT
octahydroquinline 6f (0.323 g, 1.03 mmol) after purification by chromatography on basic alumina (2% ethyl
20
acetate in n-hexanes) gave title compound 7c (0.235 g, 72%) as a yellow oil. [α]D +45 (c 1.0, CHCl3); RF =
0.75 (1:1 n-hexanes, ethyl acetate); νmax/cm-1 2973, 2930, 2870, 1720, 1449, 1367, 1324, 1186, 1153, 1029; δH
(400 MHz; CDCl3), 1.14-1.22 (1H, m, HA-8), 1.9 (3H, t, J = 7.2 Hz, OCH2CH3), 1.27-1.30 (3H, m,
NCH(CH3)Ph), 1.32-1.46 (2H, m, H-6), 1.43-1.77 (6H, m, H-4, H-5, H-7), 1.79-1.86 (1H, m, H-4a), 2.00-2.08
(1H, m, HB-8), 2.40-2.53 (2H, m, HA-2, H-3), 2.64 (1H, d, J = 5.6 Hz, HB-2), 3.05 (1H, dt, J = 3.5, 12.0 Hz, H-
8a), 3.66 (1H, q, J = 6.4 Hz, NCH(CH3)Ph), 4.01-4.05 (2H, m, OCH2CH3), 7.21-7.35 (5H, m, Ar-H); δC (100
MHz; CDCl3) 14.1 (OCH2CH3), 18.0 (NCH(CH3)Ph), 21.0 (C-7), 22.2 (C-6), 25.6 (C-8), 27.6 (C-4), 31.6 (C-5),
34.7 (C-4a), 42.3 (C-3), 45.4 (C-2), 55.1 (NCH(CH3)Ph), 60.0 (C-8a), 60.4 (OCH2CH3), 126.5 (Ar-CH), 126.9
(Ar-CH), 128.3 (Ar-CH), 147.1 (Ar-C), 174.8 (COO); HRMS (EI+) m/z = [M]+ C20H29NO2 requires 315.21983;
found 315.21981.
4.3.4 (3S*,4aR*,9aR*)-Ethyl 1-benzyldecahydro-1H-cyclohepta[b]pyridine-3-carboxylate 7d. Using general
method B octahydroquinline 6c (0.600 g, 1.91 mmol) after purification by chromatography on basic alumina
(2% ethyl acetate in n-hexanes) gave title compound 7d (0.357 g, 58%) as a yellow oil. RF = 0.7 (4:1 n-hexanes,
ethyl acetate); νmax/cm-1 2923, 2853, 1728, 1454, 1255, 1148; δH (400 MHz; CDCl3) 0.97-1.08 (1H, m, HA-5),
1.02-1.15 (1H, m, HA-4), 1.11-1.22 (1H, m, HA-6 or HA-7), 1.22-1.32 (1H, m, HA-8), 1.23 (3H, t, J = 7.1 Hz,
OCH2CH3), 1.34-1.47 (2H, m, HB-6- or HB-7 and HA-9), 1.52-1.60 (1H, m, HB-8), 1.64-1.73 (1H, m, HB-9),
1.73-1.86 (3H, m, HB-4 and H-6 or H-7), 1.88-1.97 (1H, m, HB-5), 2.37-2.48 (1H, m, HA-2), 2.54-2.61 (1H, m,
H-3), 2.65-2.73 (1H, m, HB-2), 2.69-2.84 (1H, m, H-9a), 3.59-3.70 (2H, m, NCH2Ph), 4.03-4.13 (2H, m,
OCH2CH3) 7.14-7.37 (5H, m, Ar-H); δC (100 MHz, CDCl3) 14.2 (OCH2CH3), 20.2 (C-9), 23.3 (C-8), 28.1 (C-
4), 31.0, 31.1 (C-6, C-7), 33.5 (C-5), 36.8 (C-4a), 42.3 (C-3), 47.7 (C-2), 58.9 (NCH2Ph), 60.1 (OCH2CH3), 62.2
(C-9a), 126.7 (Ar-CH), 128.1 (Ar-CH), 128.3 (Ar-CH), 139.7 (Ar-C), 174.6 (COO); HRMS (EI+) m/z = [MH]+
C20H30NO2 requires 316.2271; found 316.2262.
4.3.5 (3S*,4aR*,9aR*)-Ethyl 1-(3-phenylpropyl)decahydro-1H-cyclohepta[b]pyridine-3-carboxylate 7e. Using
general method B octahydroquinline 6i (0.350 g, 1.02 mmol) after purification by chromatography on basic
alumina (2% ethyl acetate in n-hexanes) gave title compound 7e (0.188 g, 54%) a yellow oil; RF = 0.6 (3:1 n-
hexanes, ethyl acetate); νmax/cm-1 2931, 2850, 1721, 1451, 1247, 1155, 1031; δH (400 MHz; CDCl3) 0.96-1.07
(1H, m, HA-5), 1.11-1.20 (2H, m, HA-4 and HA-6 or HA-7), 1.23 (3H, t, J = 7.2 Hz, OCH2CH3), 1.29-1.40 (3H,
m, HA-8, HA-9 and HA-6 or HA-7), 1.51-1.65 (2H, m, HB-8, HB-9), 1.73-1.85 (4H, m, NCH2CH2CH2Ph, HB-6,
HB-7), 1.90-2.02 (2H, m, H-4a, HB-5), 2.32 (1H, t, J = 12.1 Hz, HA-2), 2.48 (1H, td, J = 2.2, 7.4 Hz,
NCH2CH2CH2Ph), 2.53-2.59 (1H, m, H-3), 2.63 (2H, t, J = 7.4 Hz, NCH2CH2CH2Ph), 2.73-2.77 (1H, m, HB-2),
2.78-2.82 (1H, m, H-9a), 4.06-4.12 (2H, m, OCH2CH3), 7.13-7.29 (5H, m, Ar-H); δC (100 MHz, CDCl3) 14.1
(OCH2CH3), 19.6 (C-9), 23.1 (C-8), 28.1 (C-4), 29.4 (NCH2CH2CH2Ph), 30.8, 31.0 (C-6, C-7), 33.4, 33.5 (C-5,
NCH2CH2CH2Ph), 36.4 (C-4a), 42.0 (C-3), 48.1 (C-2), 53.6 (NCH2CH2CH2Ph), 60.0 (OCH2CH3), 61.8 (C-9a),
125.5 (Ar-CH), 128.1 (Ar-CH), 128.3 (Ar-CH), 142.2 (Ar-C), 174.4 (COO); HRMS (EI+) m/z = [MH]+
C22H34NO2 requires 344.2584; found 344.2578.
4.3.6 (3S,4aR,9aR)-Ethyl 1-((R)-1-phenylethyl)decahydro-1H-cyclohepta[b]pyridine-3-carboxylate 7f. Using
general method B octahydroquinline 6j (0.236 g, 0.721 mmol) after purification by chromatography on basic
alumina (2% ethyl acetate in n-hexanes) gave title compound 7f (0.123 g, 52%) as a pale yellow oil. [α]D20 +68
(c 1.0, CHCl3); RF = 0.55 (3:1 n-hexanes, ethyl acetate); νmax/cm-1 2934, 2851, 1725, 1441, 1257, 1130; δH (400
MHz; CDCl3) 1.00-1.05 (1H, m, HA-5), 1.16 (3H, t, J = 7.1 Hz, OCH2CH3), 1.18-1.22 (2H, m, HA-4 and HA-6 or
HA-7), 1.25 (3H, d, J = 6.7 Hz, NCH(CH3)Ph), 1.27-1.33 (1H, m, HA-8), 1.34-1.41 (1H, m, HA-6 or HA-7), 1.56-
1.63 (3H, m, HB-8 and H-9), 1.75-1.84 (3H, m, HB-4, HB-6, HB-7), 1.93-2.07 (1H, m, HA-2), 2.39-2.45 (1H, m,
H-3), 2.55-2.61 (1H, m, HB-2), 3.15 (1H, q, J = 5.0 Hz, NCH(CH3)Ph), 3.57-3.63 (1H, m, H-9a), 4.00 (2H, q, J
= 4.0 Hz, OCH2CH3), 7.16-7.37 (5H, m, Ar-H); δC (100 MHz, CDCl3) 14.1 (OCH2CH3), 20.3 (C-9), 22.5
(NCH(CH3)Ph), 23.3 (C-8), 27.8 (C-4), 31.3, 31.7 (C-6, C-7), 33.9 (C-5), 36.6 (C-4a), 42.1 (C-3), 46.3 (C-2),
57.7 (NCH(CH3)Ph), 60.0 (OCH2CH3), 61.4 (C-9a), 126.6 (Ar-CH), 127.4 (Ar-CH), 128.3 (Ar-CH), 147.4 (Ar-
C), 174.8 (COO); HRMS (EI+) m/z = [MH]+ C21H32NO2 requires 330.2480; found 330.2483.
4.3.7 (3S*,4aS*,8aR*)-Ethyl 1-benzyl-5,7-dimethyldecahydroquinoline-3-carboxylate 7g. Using general method
B octahydroquinline 6b (0.215 g, 0.67 mmol) after purification by chromatography on basic alumina (2% ethyl
acetate in n-hexanes) gave title compound 7g (0.091 g, 42%) as a pale yellow oil. RF = 0.8 (4:1 n-hexanes, ethyl
11

acetate); νmax/cm-1 2968, 2950, 2855, 1714, 1495, 1455, 1368, 1239, 1200, 1160, 1064; δH (400 MHz; CDCl3)
ACCEPTED MANUSCRIPT
0.67-0.77 (1H, m, HA-6), 0.81 (3H, t, J = 6.6 Hz, 5-CH3), 0.89 (3H, t, J = 6.6 Hz, 7-CH3), 0.99-1.09 (1H, m, HA-
8), 1.18 (3H, t, J = 7.2 Hz, OCH2CH3), 1.25-1.33 (1H, m, H-4a), 1.42-1.51 (1H, m, HA-4), 1.72-1.80 (1H, m,
HB-6), 1.84-2.00 (2H, m, H-5 and HA-2), 2.12-2.23 (3H, m, HB-4, H-7 and HB-8), 2.35-2.41 (1H, m, H-8a),
2.59-2.69 (1H, m, H-3), 2.91 (1H, d, J = 13.3 Hz, NCHAHBPh), 2.95-3.00 (1H, m, HB-2), 4.00-4.08 (2H, m,
OCH2CH3), 4.11 (1H, d, J = 13.6 Hz, NCHAHBPh), 7.19-7.34 (5H, m, Ar-H); δC (100 MHz, CDCl3) 14.1
(OCH2CH3), 19.7 (7-CH3), 22.6 (5-CH3), 26.2 (C-5), 28.5 (C-7), 30.3 (C-4), 37.6 (C-4a), 38.7 (C-8), 43.6 (C-3),
45.2 (C-6), 55.2 (C-2), 56.7 (NCH2Ph), 60.1 (OCH2CH3), 61.7 (C-8a), 126.6 (Ar-CH), 127.8 (Ar-CH), 128.6
(Ar-CH), 140.1 (Ar-C), 174.9 (COO); HRMS (EI+) m/z = [MH]+ C21H32NO2 requires 330.2428; found
330.2422.
4.3.8 (3S*,4aS*,8aR*)-Ethyl 5,7-dimethyl-1-(3-phenylpropyl)decahydroquinoline-3-carboxylate 7h. Using
general method B octahydroquinline 6g (0.400 g, 1.13 mmol) after purification by chromatography on basic
alumina (2% ethyl acetate in n-hexanes) gave title compound 7h (0.174 g, 43%) as a pale yellow oil. RF = 0.7
(3:1 n-hexanes, ethyl acetate); νmax/cm-1 2994, 2866, 1730, 1453, 1182, 1153; δH (400 MHz; CDCl3) 0.58-0.70
(1H, m, HA-6), 0.77 (3H, d, J = 6.5 Hz, 5-CH3), 0.84 (3H, d, J = 6.5 Hz, 7-CH3), 0.83-0.94 (1H, m, HA-8), 1.14-
1.22 (1H, m, H-3), 1.24 (3H, t, J = 7.1 Hz, OCH2CH3), 1.39 (1H, td, J = 4.6, 13.3 Hz, NCH2CHAHBCH2Ph),
1.60-1.90 (5H, m, H-4, H-5, HB-6, HB-8), 1.91-2.01 (1H, m, H-7), 2.12-2.20 (1H, m, NCH2CHAHBCH2Ph), 2.23
(1H, t, J = 11.3 Hz, NCHAHBCH2CH2Ph), 2.28-2.33 (1H, m, H-8a), 2.34-2.44 (1H, m, HA-2), 2.47-2.71 (4H, m,
HB-2, H-4a, NCH2CH2CH2Ph), 3.07-3.14 (1H, m, NCHAHBCH2CH2Ph), 4.10 (2H, q, J = 7.1 Hz, OCH2CH3),
7.12-7.32 (5H, m, Ar-CH); δC (100 MHz, CDCl3) 14.2 (OCH2CH3), 19.7 (7-CH3), 22.5 (5-CH3), 25.4 (C-4),
26.3 (C-5), 28.4 (C-7), 30.0 (NCH2CH2CH2Ph), 33.8 (NCH2CH2CH2Ph), 37.8 (C-4a), 38.2 (C-8), 43.2 (C-3),
45.0 (C-6), 52.0 (C-2), 55.1 (NCH2CH2CH2Ph), 60.0 (C-8a), 60.1 (OCH2CH3), 125.7 (CH, Par-CH), 128.2 (Ar-
CH), 128.3 (Ar-CH), 142.3 (Ar-C), 174.9 (COO); HRMS (EI+) m/z = [MH]+ C23H36NO2 requires 358.2741;
found 358.2748.
4.4 General Method C: Reduction of esters 7 to alcohols 8. To a solution of lithium aluminium hydride (3.0
mmol) in dry THF (2.0 mL) was added dropwise a solution of ester 7 (1.0 mmol) in dry THF (8.0 mL) and the
mixture was stirred for 15 min. The reaction was quenched by the dropwise addition of 5.2 M potassium
hydroxide (1.2 mL) and stirring continued for 15 min. The resultant mixture was filtered through Celite and
washed with ethyl acetate (40 mL). The volatile solvents were removed in vacuo to give the desired alcohol 8,
which was used without further purification.
4.4.1 ((3S*,4aR*,8aR*)-1-Benzyldecahydroquinolin-3-yl)methanol 8a. Using general method C ester 7a (0.277
g, 0.964 mmol) gave the title compound 8a (0.195 g, quant.) as a pale yellow oil, which was used without
further purification. RF = 0.2 (1:1 n-hexanes, ethyl acetate); νmax/cm-1 3352, 3027, 2920, 2852, 1494, 1451, 1369,
1069, 1036, 735, 700; δH (400 MHz; CDCl3) 1.02-1.18 (1H, m, HA-7), 1.23-1.29 (2H, m, H-6), 1.29-1.39 (2H,
m, H-4), 1.48-1.64 (4H, m, H-5, H-8), 1.70-1.77 (1H, m, HB-7), 1.81-1.92 (1H, m, H-3), 2.01-2.08 (1H, m, H-
4a), 2.15-2.21 (1H, m, HA-2), 2.63 (1H, d, J = 11.4 Hz, HB-2), 2.72-2.82 (1H, m, H-8a), 3.42-3.45 (2H, m,
CH2OH), 3.58 (1H, dd, J = 2.6, 13.6 Hz, NCHACHBPh), 3.73 (1H, dd, J = 2.6, 13.6 Hz, NCHACHBPh), 7.20-
7.34 (5H, m, Ar-H); δC (100 MHz; CDCl3) 17.5 (C-8), 20.8 (C-6), 25.4 (C-7), 27.0 (C-4), 31.5 (C-5), 34.9 (C-
4a), 39.0 (C-3), 48.6 (C-2), 58.4 (NCH2Ph), 59.1 (C-8a), 66.1 (CH2OH), 126.5 (Ar-CH), 128.1 (Ar-CH), 128.4
(Ar-CH), 139.6 (Ar-C); HRMS (EI+) m/z = [M]+ C17H25NO requires 258.20275; found 258.20298.
4.4.2 ((3S*,4aR*,8aR*)-1-(3-Phenylpropyl)decahydroquinolin-3-yl)methanol 8b. Using general method C ester
7b (0.350 g, 1.07 mmol) gave title compound 8b (0.130 g, quant.) as a pale yellow oil, which was used without
further purification. RF = 0.25 (1:1 n-hexanes, ethyl acetate); νmax/cm-1 3444, 3025, 2923, 2853, 1495, 1449,
1371, 1080, 1043, 730, 698; δH (300 MHz; CDCl3) 1.10-1.20 (1H, m, HA-7), 1.29-1.37 (2H, m, H-4), 1.39-1.42
(2H, m, H-6), 1.43-1.50 (2H, m, H-8), 1.58-1.62 (2H, m, H-5), 1.78-1.82 (1H, m, HB-7), 1.85-1.93 (3H, m, H-3,
NCH2CH2CH2Ph), 1.94-2.08 (1H, m, H-4a), 2.12-2.19 (1H, m, HA-2), 2.40-2.54 (2H, m, NCH2CH2CH2Ph),
2.55-2.71 (2H, m, NCH2CH2CH2Ph), 2.74-2.76 (1H, m, HB-2), 2.79-2.81 (1H, m, H-8a), 3.41-3.55 (2H, m,
CH2OH) 7.22-7.35 (5H, m, Ar-H); δC (75.5 MHz; CDCl3) 17.0 (C-8), 21.0 (C-6), 25.6 (C-7), 27.2 (C-4), 29.4
(NCH2CH2CH2Ph), 31.7 (C-5), 33.8 (NCH2CH2CH2Ph), 35.2 (C-4a), 39.4 (C-3), 49.5 (C-2), 53.7
(NCH2CH2CH2Ph), 58.8 (C-8a), 66.41 (CH2OH), 125.6 (Ar-CH), 128.2 (Ar-CH), 128.3 (Ar-CH), 142.3 (Ar-C);
MS (EI): m/z = 287 (M+, 32), 244 (97), 182 (100), 91 (27), 44 (21); ); HRMS (EI+) m/z = [MH]+ C21H29NO2
C19H29NO2 requires 287.2249; found 287.2248.
12

4.4.3 ((3S,4aR,8aR)-1-((R)-1-Phenylethyl)decahydroquinolin-3-yl)methanol 8c. Using general method C ester
ACCEPTED MANUSCRIPT
7c (0.235 g, 0.740 mmol) gave 8c (0.202 g, quant.) as a pale yellow solid, which was used without further
20
purification. [α]D +44 (c 1.0, CHCl3); m.p. 109-110 °C; RF = 0.15 (1:1 n-hexanes, ethyl acetate); νmax/cm-1
3285, 3027, 2920, 2871, 1450, 1368, 1070, 1040, 761, 701; δH (400 MHz; CDCl3) 1.11-1.22 (1H, m, HA-7),
1.27 (3H, t, J = 7.4 Hz, NCH(CH3)Ph), 1.30-1.43 (4H, m, H-4, H-6), 1.46-1.63 (4H, m, H-5, H-8), 1.65-1.78
(1H, m, HB-7), 1.95-2.08 (3H, m, HA-2, H-3, H-4a), 2.46 (1H, dd, J = 3.8, 11.6 Hz, HB-2), 3.08-3.12 (1H, m, H-
8a), 3.35 (2H, d, J = 6.0 Hz, CH2OH), 3.61 (1H, q, J = 6.5 Hz, NCH(CH3)Ph), 7.17-7.31 (5H, m, Ar-H); δC (100
MHz; CDCl3) 17.6 (C-8), 21.1 (NCH(CH3)Ph), 22.1 (C-6), 25.9 (C-7), 27.5 (C-4), 31.9 (C-5), 35.2 (C-4a), 39.3
(C-3), 47.1 (C-2), 55.6 (NCH(CH3)Ph), 60.7 (C-8a), 66.6 (CH2OH), 126.5 (Ar-CH), 127.0 (Ar-CH), 128.3 (Ar-
CH), 147.4 (Ar-C); HRMS (EI+) m/z = [M]+ C18H27NO2 requires 273.21533; found 273.21513.
4.4.4 ((3S*,4aR*,9aR*)-1-Benzyldecahydro-1H-cyclohepta[b]pyridin-3-yl)methanol 8d. Using general method C
ester 7d (0.147 g, 0.466 mmol) gave title compound 8d (0.127 g, quant.) as a pale yellow oil, which was used
without further purification. RF = 0.1 (2:1 n-hexanes, ethyl acetate); νmax/cm-1 3336, 2917, 2851, 1453, 1355,
1063, 1026; δH (400 MHz; CDCl3) 0.93-1.06 (4H, m, H-5 and H-6 or H-7), 1.26-1.33 (1H, m, HA-8), 1.33-1.41
(1H, m, HA-9), 1.52-1.61 (1H, m, HB-8), 1.54-1.61 (1H, m, HA-6 or HA-7), 1.64-1.71 (1H, m, HB-9), 1.74-1.80
(1H, m, HB-6 or HB-7), 1.76-1.84 (2H, m, H-4), 1.80-1.89 (1H, m, H-3), 2.01-2.07 (1H, m, HA-2), 2.02-2.11
(1H, m, H-4a), 2.55-2.62 (1H, m, HB-2), 2.75-2.83 (1H, m, H-9a), 3.38-3.48 (2H, m, NCH2Ph), 3.62 (2H, q, J =
7.6 Hz, CH2OH), 7.18-7.44 (5H, m, Ar-H); δC (100 MHz, CDCl3) 20.1 (C-9), 23.4 (C-8), 28.2 (C-4), 31.2, 31.3
(C-6, C-7), 33.9 (C-5), 37.1 (C-4a), 39.2 (C-3), 49.3 (C-2), 59.2 (NCH2Ph), 62.9 (C-9a), 66.7 (CH2OH), 126.6
(Ar-CH), 128.1 (Ar-CH), 128.5 (Ar-CH), 140.3 (Ar-C); ); HRMS (EI+) m/z = [MH]+ C18H28NO requires
274.2165; found 247.2162.
4.4.5 ((3S*,4aR*,9aR*)-1-(3-Phenylpropyl)decahydro-1H-cyclohepta[b]pyridin-3-yl)methanol 8e. Using general
method C ester 7e (0.160 g, 0.465 mmol) gave title compound 8e (0.125 g, quant.) as a yellow oil, which was
used without further purification. RF = 0.3 (1:1 n-hexanes, ethyl acetate); νmax/cm-1 3344, 2920, 2852, 1453,
1373, 1105, 1029; δH (400 MHz; CDCl3) 0.88-1.02 (3H, m, HA-5, and H-6 or H-7), 1.10-1.20 (1H, m, HA-4),
1.22-1.38 (3H, m, HB-4, HA-8, HA-9), 1.48-1.62 (4H, m, HB-8, HB-9 and H-6 or H-7), 1.73-1.84, 1.73-1.84 (3H,
m, H-3, NCH2CH2CH2Ph), 1.88-2.02 (3H, m, HA-2, H-4a, HB-5), 2.46 (2H, t, J = 7.7 Hz, NCH2CH2CH2Ph),
2.58-2.68 (3H, m, HB-2, NCH2CH2CH2Ph), 2.79-2.86 (1H, m, H-9a), 3.35-3.50 (2H, m, CH2OH), 7.14-7.31
(5H, m, Ar-H); δC (100 MHz, CDCl3) 19.3 (C-9), 23.3 (C-8), 28.3 (C-4), 29.5 (NCH2CH2CH2Ph), 31.1, 31.3 (C-
6, C-7), 33.8 (C-5, NCH2CH2CH2Ph), 37.0 (C-4a), 39.1 (C-3), 50.0 (C-2), 54.1 (NCH2CH2CH2Ph), 62.2 (C-9a),
66.5 (CH2OH), 125.6 (Ar-CH), 128.2 (Ar-CH), 128.4 (Ar-CH), 142.4 (Ar-C); HRMS (EI+) m/z = [MH]+
C20H32NO requires 302.2478; found 302.2483.
4.4.6 ((3S,4aR,9aR)-1-((R)-1-Phenylethyl)decahydro-1H-cyclohepta[b]pyridin-3-yl)methanol 8f. To Using
general method C ester 7f (0.100 g, 0.30 mmol) gave title compound 8f (0.086 g, quant.) as a pale yellow oil,
20
which was used without further purification. [α]D +72 (c 1.0, CHCl3); RF = 0.2 (1:1 n-hexanes, ethyl acetate);
νmax/cm-1 3331, 2929, 2842, 1451, 1347, 1063, 1011; δH (400 MHz; CDCl3) 0.94-1.09 (2H, m, HA-5 and HA-6 or
HA-7), 1.23-1.31 (4H, m, HA-4, NCH(CH3)Ph), 1.36-1.45 (2H, m, HA-8, HA-9), 1.53-1.71 (4H, m, H-3, HB-8,
HB-9 and HB-6 or HB-7), 1.78-1.89 (4H, m, HA-2, HB-4, and H-6 or H-7), 1.94-2.02 (1H, m, HB-5), 2.04-2.11
(1H, m, H-4a), 2.41-2.47 (1H, m, HB-2), 3.18 (1H, q, J = 5.0 Hz, NCH(CH3)Ph), 3.31 (2H, dd, J = 1.6, 6.1 Hz,
CH2OH), 3.56-3.36 (1H, m, H-9a), 7.16-7.34 (5H, m, Ar-H); δC (100 MHz, CDCl3) 19.8 (C-9), 22.2
(NCH(CH3)Ph), 23.4 (C-8), 27.8 (C-4), 31.3, 31.8 (C-6, C-7), 34.3 (C-5), 37.1 (C-4a), 39.0 (C-3), 47.8 (C-2),
58.1 (NCH(CH3)Ph), 61.3 (C-9a), 66.6 (CH2OH), 126.5 (Ar-CH), 127.3 (Ar-CH), 128.4 (Ar-CH), 147.6 (Ar-C);
HRMS (EI+) m/z = [MH]+ C19H30NO requires 288.2322; found 288.2321.
4.4.7 ((3S*,4aS*,8aR*)-1-Benzyl-5,7-dimethyldecahydroquinolin-3-yl)methanol 8g. Using general method C
ester 7g (0.08 g, 0.24 mmol) gave title compound 8g (0.069 g, quant.) as a pale yellow oil, which was used
without further purification. RF = 0.18 (1:1 n-hexanes, ethyl acetate); νmax/cm-1 3303, 2918, 2860, 1494, 1375,
1121, 1015; δH (400 MHz; CDCl3) 0.65-0.76 (1H, m, HA-6), 0.81 (3H, d, J = 6.7 Hz, 5-CH3), 0.86 (3H, d, J =
6.7 Hz, 7-CH3), 0.96-1.11 (2H, m, HA-4 and HA-8), 1.21-1.23 (1H, m, H-3), 1.46-1.54 (1H, m, HA-2), 1.70-1.77
(1H, m, HB-6), 1.81-1.96 (3H, m, H-4a, HB-4, H-5), 2.12-2.22 (2H, m, H-7, HB-8), 2.27-2.31 (1H, m, H-8a),
2.86-2.93 (2H, m, HB-2, NCHAHBPh), 3.21-3.32 (2H, m, CH2OH), 4.10 (1H, d, J = 13.6 Hz, NCHAHBPh), 7.16-
7.37 (5H, m, Ar-CH); δC (100 MHz, CDCl3) 19.6 (7-CH3), 22.6 (5-CH3), 26.2 (C-5), 28.8 (C-7), 30.3 (C-4),
34.0 (C-4a), 38.9 (C-8), 43.9 (C-3), 45.3 (C-6), 57.0 and 57.1 (C-2, NCH2Ph), 62.1 (C-8a), 66.8 (CH2OH),
13

126.5 (Ar-CH), 128.1 (Ar-CH), 128.6 (Ar-CH), 140.2 (Ar-C); HRMS (EI+) m/z = [MH]+ C19H30NO requires
ACCEPTED MANUSCRIPT
288.2322; found 288.2327.
4.4.8 ((3S*,4aS*,8aR*)-5,7-Dimethyl-1-(3-phenylpropyl)decahydroquinolin-3-yl)methanol 8h. Using general
method C ester 7h (0.084 g, 0.24 mmol) gave title compound 8h (0.072 g, quant.) as a pale yellow oil, which
was used without further purification. RF = 0.25 (1:1 n-hexanes, ethyl acetate); νmax/cm-1 3318, 2918, 2868,
1453, 1375, 1114, 1076, 1038; δH (400 MHz; CDCl3) 0.56-0.66 (1H, m, HA-6), 0.78 (3H, d, J = 6.5 Hz, 5-CH3),
0.82 (3H, d, J = 6.5 Hz, 7-CH3), 0.83-0.94 (2H, m, HA-8, NCH2CHAHBCH2Ph), 1.11-1.19 (1H, m, H-3), 1.62-
1.91 (7H, m, H-4, H-4a, H-5, HB-8, NCHAHBCH2CH2Ph, NCH2CHAHBCH2Ph), 1.94-2.03 (1H, m, H-7), 2.25-
2.30 (1H, m, H-8a), 2.37-2.70 (4H, m, H-2, NCH2CH2CH2Ph), 3.00-3.06 (1H, m, NCHAHBCH2CH2Ph), 3.28-
3.46 (2H, m, CH2OH), 7.13-7.29 (5H, m, Ar-CH); δC (100 MHz, CDCl3) 19.7 (7-CH3), 22.5 (5-CH3), 25.0 (C-
4), 26.3 (C-5), 28.7 (C-7), 30.1 (NCH2CH2CH2Ph), 33.8 (NCH2CH2CH2Ph), 34.4 (C-4a), 38.2 (C-8), 43.5 (C-3),
45.0 (C-6), 52.4 (C-2), 57.0 (NCH2CH2CH2Ph), 60.5 (C-8a), 66.9 (CH2OH), 125.6 (Ar-CH), 128.2 (Ar-CH),
128.3 (Ar-CH), 142.3 (Ar-C); HRMS (EI+) m/z = [MH]+ C21H34NO requires 316.2635; found 316.2647.
4.5 General Method D: Preparation of anthranilate esters 10. To a solution of alcohol 8 (1.0 mmol) in dry
dichloromethane (15 mL) was added acid 9 (2.0 mmol), DMAP (0.1 mmol) and DCC (2.0 mmol) and the
mixture was stirred for 18 h. The mixture was filtered through Celite and washed with ethyl acetate (90 mL).
The filtered mixture was washed with aqueous NaHCO3 (2 × 90 mL), dried (Na2SO4) and the volatile solvents
were removed in vacuo to give the crude product which was purified by flash column chromatography to give
the desired anthranilate ester 10.
4.5.1 ((3′′S*,4a′′R*,8a′′R*)-1′′-Benzyldecahydroquinolin-3′′-yl)methyl 2-(3′-methyl-2′,5′-dioxo-2′,5′-dihydro-1H-
pyrrol-1′-yl)benzoate 10a. Using general method D alcohol 8a (0.080 g, 0.310 mmol) after purification by flash
chromatography (20% n-hexanes in ethyl acetate) gave title compound 10a (0.077 g, 53%) as a green oil. RF =
0.7 (4:1 ethyl acetate, n-hexanes,); νmax/cm-1 3025, 2929, 1727, 1714, 1602, 1494, 1454, 1393, 1292, 1259,
1108; δH (400 MHz; CDCl3) 1.04-1.14 (1H, m, HA-7″), 1.26-1.31 (2H, m, H-6″), 1.34-1.43 (2H, m, H-4″), 1.46-
1.61 (4H, m, H-5″, H-8″), 1.69-1.79 (1H, m, HB-7″), 1.87-1.94 (1H, m, H-3″), 1.97-2.10 (4H, m, H-4a″, 3ʹ-
CH3), 2.22 (1H, t, J = 11.2 Hz, HA-2″), 2.58 (1H, dd, J = 3.2, 11.2 Hz, HB-2″), 2.73-2.78 (1H, m, H-8a″), 3.58
(1H, d, J = 13.6 Hz, NCHAHBPh), 3.73 (1H, d, J = 13.6 Hz, NCHAHBPh), 4.01-4.14 (2H, m, CH2O), 6.45 (1H, s,
H-4′), 7.21-7.34 (6H, m, H-6, Ar-H), 7.44 (1H, t, J = 8.0 Hz, H-5), 7.61 (1H, t, J = 8.0 Hz, H-4), 7.95 (1H, d, J =
8.0 Hz, H-3); δC (100 MHz; CDCl3) 11.1 (3′-CH3), 17.6 (C-8″), 20.94 (C-6″), 25.4 (C-7″), 27.3 (C-4″), 31.5 (C-
5″), 35.0 (C-4a″), 36.1 (C-3″), 48.4 (C-2″), 58.4 (NCH2Ph), 58.9 (C-8a″), 68.3 (CH2O), 126.6 (Ar-CH), 127.8
(C-4′), 128.0 (C-1), 128.1 (Ar-CH), 128.5 (Ar-CH), 128.8 (C-5), 130.2 (C-6), 131.4 (C-3), 131.6 (C-2), 133.1
(C-4), 139.7 (Ar-C), 146.1 (C-3′), 164.7 (COO), 169.64 (C-2ʹ), 170.7 (C-5ʹ); HRMS (EI+) m/z = [M]+
C29H32N2O4 requires 427.23621; found 427.23547.
4.5.2 ((3′′S*,4a′′R*,8a′′R*)-1′′-(3-Phenylpropyl)decahydroquinolin-3′′-yl)methyl 2-(3′-methyl-2′,5′-dioxo-2′,5′-
dihydro-1H-pyrrol-1′-yl) 10b. Using general method D alcohol 8b (0.112 g, 0.390 mmol) after purification by
flash chromatography (20% n-hexanes in ethyl acetate) gave title compound 10b (0.180 g, 95%) as a dark green
oil. RF = 0.65 (4:1 ethyl acetate, n-hexanes,); νmax/cm-1 3028, 2927, 1727, 1715, 1600, 1494, 1398, 1290, 1106;
δH (400 MHz; CDCl3) 1.03-1.1.17 (1H, m, HA-7″), 1.29-1.40 (4H, m, H-4″, H-6″), 1.41-1.50 (2H, m, H-8″),
1.54-1.59 (2H, m, H-5″), 1.68-1.84 (3H, m, HB-7″, NCH2CH2CH2Ph), 1.98-2.09 (2H, m, H-3″, H-4a″), 2.10-
2.20 (4H, m, HA-2″, 3ʹ-CH3), 2.44-2.57 (2H, m, NCH2CH2CH2Ph), 2.61-2.65 (3H, m, HB-2″, NCH2CH2CH2Ph),
2.76-2.80 (1H, m, H-8a″), 4.04-4.21 (2H, m, CH2O), 6.48 (1H, t, J = 1.7 Hz, H-4′), 7.15-7.30 (6H, m, H-6, Ar-
H), 7.49 (1H, dt, J = 1.2, 7.8 Hz, H-5), 7.61 (1H, dt, J = 1.2, 7.8 Hz, H-4), 8.07 (1H, dd, J = 1.2, 7.8 Hz, H-3);
δC (100 MHz; CDCl3) 11.1 (3′-CH3), 16.9 (C-8″), 20.9 (C-6″), 25.5 (C-7″), 27.3 (C-4″), 29.4
(NCH2CH2CH2Ph), 31.5 (C-5″), 33.7 (NCH2CH2CH2Ph), 35.1 (C-4a″), 36.1 (C-3″), 49.1 (C-2″), 53.4
(NCH2CH2CH2Ph), 58.5 (C-8a″), 68.4 (CH2O), 125.6 (Ar-CH), 127.9 (C-4′), 128.1 (C-1), 128.2 (Ar-CH), 128.3
(Ar-CH), 128.9 (C-5), 130.3 (C-6), 131.5 (C-3), 131.6 (C-2), 133.1 (C-4), 142.3 (Ar-C), 146.2 (C-3′), 164.8
(COO), 169.7 (C-2ʹ), 170.7 (C-5ʹ); HRMS (EI+) m/z = [M]+ C31H36N2O4 requires 500.26751; found 500.26752.
4.5.3 ((3′′S,4a′′R,8a′′R)-1′′-((R)-1-Phenylethyl)decahydroquinolin-3′′-yl)methyl 2-(3′-methyl-2′,5′-dioxo-2′,5′-
dihydro-1H-pyrrol-1′-yl)benzoate 10c. Using general method D alcohol 8c (0.100 g, 0.360 mmol) after
purification by flash chromatography (20% n-hexanes in ethyl acetate) gave title compound 10c (0.121 g, 70%)
20
as a green oil. [α]D +46 (c 1.0, CHCl3); RF = 0.5 (4:1 ethyl acetate, n-hexanes,); νmax/cm-1 2931, 2852, 1710,
14

1602, 1492, 1452, 1394, 1244, 1208, 1109, 1108; δH (400 MHz; CDCl3) 1.01-1.19 (1H, m, HA-7″), 1.22-1.26
ACCEPTED MANUSCRIPT
(3H, m, NCH(CH3)Ph), 1.29-1.44 (4H, m, H-4″, H-6″), 1.52-1.63 (4H, m, H-5″, H-8″), 1.71-1.80 (1H, m, HB-
7″), 1.89-2.08 (3H, m, HA-2″, H-3″, H-4a″), 2.13 (3H, s, 3ʹ-CH3), 2.52 (1H, d, J = 9.2 Hz, HB-2″), 3.10-3.17
(1H, m, H-8a″), 3.61 (1H, q, J = 6.5 Hz, NCH(CH3)Ph), 3.82-2.87 (1H, m, CHAHBO), 3.96-4.01 (1H, m,
CHAHBO), 6.45-6.46 (1H, m, H-4′), 7.21-7.39 (7H, m, H-5, H-6, Ar-H), 7.56-7.65 (2H, m, H-3, H-4); δC (100
MHz; CDCl3) 11.0 (3′-CH3), 17.4 (C-8″), 20.9 (C-6″), 21.0 (NCH(CH3)Ph), 25.5 (C-7″), 27.4 (C-4″), 31.7 (C-
5″), 35.2 (C-4a″), 36.2 (C-3″), 47.0 (C-2″), 55.3 (NCH(CH3)Ph), 60.5 (C-8a″), 70.0 (CH2O), 126.5 (Ar-CH),
127.0 (C-4′), 127.8 (C-1), 127.9 (Ar-CH), 128.2 (Ar-CH), 128.8 (C-5), 130.1 (C-6), 131.2 (C-3), 131.6 (C-2),
132.9 (C-4), 146.0 (C-3ʹ, Ar-C), 164.44 (COO), 169.4 (C-2ʹ), 170.7 (C-5ʹ); HRMS (EI+) m/z = [M]+
C30H34N2O4 requires 486.25186; found 486.25221.
4.5.4 ((3′′S*,4a′′R*,9a′′R*)-1′′-Benzyldecahydro-1I-cyclohepta[b]pyridin-3′′-yl)methyl 2-(3′-methyl-2′,5′-dioxo-
2′,5′-dihydro-1I-pyrrol-1′-yl)benzoate 10d. Using general method D alcohol 8d (0.120 g, 0.44 mmol) after
purification by flash chromatography (50% n-hexanes in ethyl acetate) gave title compound 10d (0.167 g, 78%)
as a light green oil. RF = 0.55 (3:1 ethyl acetate, n-hexanes,); νmax/cm-1 2930, 1715, 1497, 1453, 1371, 1260,
1072; δH (400 MHz; CDCl3) 0.94-1.19 (4H, m, HA-4ʹʹ, HA-5ʹʹ, HA-6ʹʹ, HA-7ʹʹ), 1.21-1.30 (1H, m, HA-8ʹʹ), 1.31-
1.40 (1H, m, HA-9ʹʹ), 1.50-1.61 (2H, m, HB-6ʹʹor HB-7ʹʹand 8ʹʹ-HB), 1.62-1.70 (1H, m, HB-9ʹʹ), 1.71-1.81 (2H, m,
HB-4ʹʹ and HB-6ʹʹ or HB-7ʹʹ), 1.85-1.94 (1H, m, HB-5ʹʹ), 1.95-2.00 (3H, m, HA-2ʹʹ, H-3ʹʹ, H-4aʹʹ), 2.15 (3H, s, 3ʹ-
CH3), 2.56 (1H, d, J = 9.2 Hz, HB-2ʹʹ), 2.77-2.83 (1H, m, H-9aʹʹ), 3.58-3.69 (2H, m, NCH2Ph), 3.91-4.05 (2H, m,
CH2O), 6.44 (1H, s, H-4ʹ), 7.19-7.35 (6H, m, H-6, Ar-H), 7.44 (1H, td, J = 1.4, 7.5 Hz, H-5), 7.61 (1H, td, J =
1.4, 7.5 Hz, H-4), 7.93 (1H, dd, J = 1.4, 7.5 Hz, H-3); δC (100 MHz, CDCl3) 11.1 (3ʹ-CH3), 19.8 (C-9ʹʹ), 23.3 (C-
8ʹʹ), 28.0 (C-4ʹʹ), 31.1, 31.4 (C-6ʹʹ, C-7ʹʹ), 33.7 (C-5ʹʹ), 36.0 (C-4aʹʹ), 37.0 (C-3ʹʹ), 49.1 (C-2ʹʹ), 58.8 (NCH2Ph),
62.1 (C-9aʹʹ), 68.1 (CH2O), 126.6 (Ar-CH), 127.8 (C-1), 128.1 (2 × Ar-CH), 128.5 (C-4ʹ), 128.8 (C-5), 130.2
(C-6), 131.4 (C-3), 131.5 (C-2), 133.0 (C-4), 139.5 (Ar-C), 146.1 (C-3ʹ), 164.7 (COO), 169.6 (C-2ʹ), 170.7 (C-
5ʹ); HRMS (EI+) m/z = [MH]+ C30H35N2O4 requires 487.2591; found 487.2580.
4.5.5 ((3′′S*,4a′′R*,9a′′R*)-1′′-(3-Phenylpropyl)decahydro-1H-cyclohepta[b]pyridin-3′′-yl)methyl 2-(3′-methyl-
2′,5′-dioxo-2′,5′-dihydro-1H-pyrrol-1′-yl)benzoate 10e. Using general method D alcohol 8e (0.120 g, 0.40
mmol) after purification by flash chromatography (50% n-hexanes in ethyl acetate) gave title compound 10e
(0.136 g, 64%) as a green oil. RF = 0.45 (1:1 ethyl acetate, n-hexanes,); νmax/cm-1 2928, 2853, 1709, 1585, 1449,
1256, 1134, 1085; δH (400 MHz; CDCl3) 0.93-1.04 (3H, m, HA-5ʹʹ and H-6ʹʹ or H-7ʹʹ), 1.13-1.19 (2H, m, H-4ʹʹ),
1.23-1.40 (2H, m, HA-8ʹʹ, HA-9ʹʹ), 1.50-1.62 (4H, m, HB-8ʹʹ, HB-9ʹʹ, and H-6ʹʹ or H-7ʹʹ), 1.74-1.84 (2H, m,
NCH2CH2CH2Ph), 1.90-2.03 (4H, m, HA-2ʹʹ, H-3ʹʹ, H-4aʹʹ, HB-5ʹʹ), 2.16 (3H, s, 3ʹ-CH3), 2.46 (2H, t, J = 7.4 Hz,
NCH2CH2CH2Ph), 2.57 (1H, d, J = 7.4 Hz, HB-2ʹʹ), 2.63 (2H, t, J = 7.3 Hz, NCH2CH2CH2Ph), 2.80-2.86 (1H,
m, H-9aʹʹ), 3.97-4.07 (2H, m, CH2O), 6.47 (1H, s, H-4ʹ), 7.16-7.32 (6H, m, H-6, Ar-H), 7.50 (1H, td, J = 1.3, 7.7
Hz, H-5), 7.64 (1H, td, J = 1.3, 7.7 Hz, H-4), 8.06 (1H, dd, J = 1.3, 7.7 Hz, H-3); δC (100 MHz, CDCl3) 11.2 (3ʹ-
CH3), 19.1 (C-9ʹʹ), 23.3 (C-8ʹʹ), 28.3 (C-4ʹʹ), 29.6 (NCH2CH2CH2Ph), 31.2, 31.5 (C-6ʹʹ, C-7ʹʹ), 33.8 (C-5ʹʹ,
NCH2CH2CH2Ph), 36.1 (C-4aʹʹ), 37.1 (C-3ʹʹ), 49.9 (C-2ʹʹ), 53.9 (NCH2CH2CH2Ph), 61.8 (C-9aʹʹ), 68.3 (CH2O),
125.6 (Ar-CH), 127.9 (C-1), 128.1 (Ar-CH), 128.3 (Ar-CH), 128.4 (C-4ʹ), 128.9 (C-5), 130.1 (C-6), 131.5 (C-3),
131.8 (C-2), 133.3 (C-4), 142.5 (Ar-C), 146.2 (C-3ʹ), 164.9 (COO), 169.6 (C-2ʹ), 170.7 (C-5ʹ); HRMS (EI+) m/z
= [MH]+ C32H39N2O4 requires 515.2904; found 515.2902.
4.5.6 ((3′′S,4a′′R,9a′′R)-1′′-((R)-1-Phenylethyl)decahydro-1H-cyclohepta[b]pyridin-3′′-yl)methyl 2-(3′-methyl-
2′,5′-dioxo-2′,5′-dihydro-1H-pyrrol-1′-yl)benzoate 10f. Using general method D alcohol 8f (0.080 g, 0.28 mmol)
after purification by flash chromatography (50% n-hexanes in ethyl acetate) gave title compound 10f (0.122 g,
20
88%) as a tan oil. [α]D +28 (c 1.0, CHCl3); RF = 0.35 (1:1 ethyl acetate, n-hexanes,); νmax/cm-1 2929, 1709,
1495, 1451, 1375, 1256, 1083; δH (400 MHz; CDCl3) 1.27 (3H, d, J = 6.7 Hz, NCH(CH3)Ph), 1.34-1.45 (2H, m,
HA-8ʹʹ, HA-9ʹʹ), 1.53-1.68 (4H, m, H-6ʹʹor H-7ʹʹ, HB-8ʹʹ, HB-9ʹʹ), 1.79-1.90 (6H, m, HA-2ʹʹ, H-4ʹʹ, H-4aʹʹ, H-6ʹʹ or
H-7ʹʹ), 1.94-2.03 (2H, m, H-5ʹʹ), 2.04-2.12 (1H, m, H-3ʹʹ), 2.49 (3H, d, J = 8.3 Hz, 3ʹ-CH3), 3.21-3.27 (1H, m,
NCH(CH3)Ph), 3.56-3.63 (1H, m, H-9aʹʹ), 3.75-3.84 (1H, m, OCHAHB), 3.92-3.97 (1H, m, OCHAHB), 7.15-7.41
(6H, m, H-4ʹ, H-2, H-3, Ar-H), 7.48-7.65 (2H, m, H-4, H-5); δC (100 MHz, CDCl3) 11.2 (3ʹ-CH3), 19.6 (C-9ʹʹ),
22.1 (NCH(CH3)Ph), 23.5 (C-8ʹʹ), 27.9 (C-4ʹʹ), 31.4, 31.9 (C-6ʹʹ, C-7ʹʹ), 34.2 (C-5ʹʹ), 36.2 (C-4aʹʹ), 37.3 (C-3ʹʹ),
48.0 (C-2ʹʹ), 57.9 (NCH(CH3)Ph), 61.2 (C-9aʹʹ), 127.8 (Ar-CH), 127.9 (C-4ʹ), 128.0 (Ar-CH) 128.8 (Ar-CH),
129.3 (C-5), 131.4 (C-6), 131.6 (C-3), 133.0 (C-4), 146.1 (C-3ʹ, Ar-C), 164.7 (COO), 169.6 (C-2ʹ), 170.6 (C-5ʹ);
HRMS (EI+) m/z = [MH]+ C31H37N2O4 requires 501.2740; found 501.2748.
15

4.5.7 ((3′′S*,4a′′S*,8a′′R*)-1′′-Benzyl-5′′,7′′-dimethyldecahydroquinolin-3′′-yl)methyl 2-(3′-methyl-2′,5′-dioxo-
ACCEPTED MANUSCRIPT
2′,5′-dihydro-1H-pyrrol-1′-yl)benzoate 10g. Using general method D alcohol 8g (0.065 g, 0.23 mmol) after
purification by flash chromatography (50% n-hexanes in ethyl acetate) gave title compound 10g (0.081 g, 70%)
as a light brown oil. RF = 0.20 (1:1 ethyl acetate, n-hexanes,); νmax/cm-1 2930, 2851, 1718, 1440, 1111; δH (400
MHz; CDCl3) 0.69-0.75 (1H, m, HA-6ʹʹ), 0.82 (3H, d, J = 6.6 Hz, 5ʹʹ-CH3), 0.85 (3H, d, J = 6.6 Hz, 7ʹʹ-CH3),
0.99-1.11 (2H, m, HA-4ʹʹ and HA-8ʹʹ), 1.24-1.30 (1H, m, H-3ʹʹ), 1.54-1.61 (1H, m, HA-2ʹʹ), 1.71-1.78 (1H, m, HB-
6ʹʹ), 1.87-2.00 (2H, m, HB-4ʹʹ and H-5ʹʹ), 2.04-2.21 (6H, m, H-4aʹʹ, H-7ʹʹ, HB-8ʹʹ, 3ʹ-CH3), 2.31-2.35 (1H, m, H-
8aʹʹ), 2.87-2.96 (2H, m, HB-2ʹʹ, NCHAHBPh), 3.80-4.00 (2H, m, CH2O), 4.08-4.15 (1H, m, NCHAHBPh), 6.44
(1H, s, H-4ʹ), 7.16-7.36 (6H, m, H-6, Ar-CH), 7.39 (1H, td, J = 1.5, 7.7 Hz, H-5), 7.60 (1H, td, J = 1.5, 7.7 Hz,
H-4), 7.76 (1H, dd, J = 1.5, 7.7 Hz, H-3); δC (100 MHz, CDCl3) 11.3 (3ʹ-CH3), 19.7 (7ʹʹ-CH3), 22.6 (5ʹʹ-CH3),
26.2 (C-5ʹʹ), 28.8 (C-7ʹʹ), 30.3 (C-4ʹʹ), 31.1 (C-4aʹʹ), 38.7 (C-8ʹʹ), 44.1 (C-3ʹʹ), 45.2 (C-6ʹʹ), 56.8 (C-2ʹʹ, NCH2Ph),
62.1 (C-8aʹʹ), 68.4 (CH2O), 126.5 (Ar-CH), 127.8 (Ar-CH), 128.0 (C-1), 128.1 (Ar-CH), 128.7 (C-4ʹ), 128.8 (C-
5), 130.2 (C-3), 131.5 (C-6), 131.6 (C-2), 133.0 (C-4), 140.0 (Ar-C), 146.1 (C-3ʹ), 164.6 (COO), 169.7 (C-2ʹ),
170.7 (C-5ʹ); HRMS (EI+) m/z = [MH]+ C31H37N2O4 requires 501.2748; found 501.2760.
4.5.8 ((3′′S*,4a′′S*,8a′′R*)-5′′,7′′-Dimethyl-1′′-(3-phenylpropyl)decahydroquinolin-3′′-yl)methyl 2-(3′-methyl-
2′,5′-dioxo-2′,5′-dihydro-1H-pyrrol-1′-yl)benzoate 10h. Using general method D alcohol 8h (0.065 g, 0.21
mmol) after purification by flash chromatography (50% n-hexanes in ethyl acetate) gave title compound 10h
(0.085 g, 77%) as a pale green oil. RF = 0.60 (2:1 ethyl acetate, n-hexanes,); νmax/cm-1 2935, 2844, 1717, 1438,
1114; δH (400 MHz; CDCl3) 0.63 (1H, q, J = 12.5 Hz, H-6ʹʹ), 0.77 (3H, d, J = 6.5 Hz, 5ʹʹ-CH3), 0.82 (3H, d, J =
6.5 Hz, 7ʹʹ-CH3), 0.86-0.94 (1H, m, HA-8ʹʹ), 0.97-1.05 (1H, m, NCH2CHACHBCH2Ph), 1.15-1.22 (1H, m, H-3ʹʹ),
1.64-1.74 (2H, m, H-5ʹʹ and HB-6ʹʹ), 1.76-2.03 (6H, m, H-4ʹʹ, H-7ʹʹ, HB-8ʹʹ, NCH2CHAHBCH2Ph,
NCHAHBCH2CH2Ph), 2.07-2.14 (1H, m, H-4aʹʹ), 2.16 (3H, s, 3ʹ-CH3), 2.28-2.33 (1H, m, H-8aʹʹ), 2.40-2.48 (1H,
m, HA-2ʹʹ), 2.49-2.56 (1H, m, NCH2CH2CHAHBPh), 2.86-2.90 (2H, m, HB-2ʹʹ, NCH2CH2CHAHBPh), 3.00-3.04
(1H, m, NCHAHBCH2CH2Ph), 3.90-4.06 (2H, m, CH2O), 6.50 (1H, s, H-4ʹ), 7.13-7.31 (6H, m, H-6, Ar-CH),
7.45-7.53 (1H, m, H-5), 7.60-7.68 (1H, m, H-4), 8.70 (1H, dd, J = 1.5, 7.6 Hz, H-3); δC (100 MHz, CDCl3) 11.1
(3ʹ-CH3), 19.7 (7ʹʹ-CH3), 22.5 (5ʹʹ-CH3), 25.0 (C-4ʹʹ), 26.4 (C-5ʹʹ), 28.7 (C-7ʹʹ), 30.1 (NCH2CH2CH2Ph), 31.3 (C-
4aʹʹ), 33.8 (NCH2CH2CH2Ph), 38.2 (C-8ʹʹ), 43.4 (C-3ʹʹ), 45.0 (C-6ʹʹ), 52.2 (C-2ʹʹ), 57.0 (NCH2CH2CH2Ph), 60.2
(C-8aʹʹ), 68.8 (CH2O), 125.7 (Ar-CH), 127.4 (C-1), 127.8 (Ar-CH), 128.2 (C-4ʹ), 128.3 (Ar-CH), 128.4 (C-5),
128.9 (C-6), 130.3 (C-3), 131.7 (C-2), 133.2 (C-4), 142.3 (Ar-C), 146.4 (C-3ʹ), 164.7 (COO), 169.7 (C-2ʹ),
170.8 (C-5ʹ); HRMS (EI+) m/z = [MH]+ C31H39N2O4 requires 529.3061; found 529.3055.
4.6 General Method E: Preparation of succinimido anthranilates 11. To a solution of anthranilate ester 10
(1.0 mmol) in ethyl acetate (15 mL) was added 10% palladium on carbon (60 mg) and the resulting mixture was
stirred under hydrogen (1 atm) for 18 h. The mixture was filtered through Celite which was washed with ethyl
acetate (50 mL) and the volatile solvents were removed in vacuo to give the desired succinimide anthranilate 11.
4.6.1 ((3′′S*,4a′′R*,8a′′R*)-1′′-Benzyldecahydroquinolin-3′′-yl)methyl 2-(3′-methyl-2′,5′-dioxopyrrolidin-1′-
yl)benzoate 11a. Using general method E anthranilate ester 10a (0.077 g, 0.160 mmol) gave title compound 11a
(0.075 g, 97%) as a tan oil. RF = 0.7 (4:1 ethyl acetate, n-hexanes,); νmax/cm-1 2926, 2853, 1713, 1603, 1493,
1389, 1290, 1259, 1184, 1036, 1082, 1044; δH (400 MHz; CDCl3) 1.05-1.14 (1H, m, HA-7″), 1.26-1.34 (2H, m,
H-6″), 1.36-1.49 (5H, m, H-4″, 3′-CH3), 1.50-1.61 (4H, m, H-5″, H-8″), 1.69-1.77 (1H, m, HB-7″), 1.83-1.97
(1H, m, H-3″), 2.00-2.12 (1H, m, H-4a″), 2.24 (1H, t, J = 11.3 Hz, HA-2″), 2.42-2.60 (2H, m, H-4′), 2.62-2.65
(1H, m, HB-2″), 2.72-2.81 (1H, m, H-8a″), 2.98-3.13 (1H, m, H-3′), 3.60 (1H, d, J = 13.4 Hz, NCHAHBPh), 3.74
(1H, d, J = 13.4 Hz, NCHAHBPh), 3.98-4.25 (2H, m, CH2O), 7.21-7.36 (6H, m, H-6, Ar-H), 7.46 (1H, dt, J =
1.3, 7.7 Hz, H-5), 7.63 (1H, dt, J = 1.3, 7.7 Hz, H-4), 7.96 (1H, d, J = 10.0 Hz, H-3); δC (100 MHz; CDCl3) 16.2
*
(3′-CH3), 16.4 (3′-CH3 ), 17.7 (C-8″), 20.9 (C-6″), 25.4 (C-7″), 27.3 (C-4″), 31.5 (C-5″), 33.9 (C-4-a″), 35.2 (C-
3ʹ), 35.5 (C-3ʹ) 36.1 (C-3ʺ), 36.9 (C-4′), 48.4 (C-2″), 58.4 (NCH2Ph), 59.0 (C-8a″), 68.1 (CH2O), 122.7 (Ar-
CH), 127.3 (C-1), 128.1 (Ar-CH), 128.5 (Ar-CH), 129.2 (C-5), 129.7 (C-6), 131.4 (C-3), 132.6 (C-2), 133.2 (C-
4), 139.6 (Ar-C), 164.1 (COO), 171.0 (C-2ʹ), 179.8 (C-5ʹ); HRMS (EI+) m/z = [M]+ C29H34N2O4 requires
474.25186; found 474.25225.
4.6.2
((3′′S*,4a′′R*,8a′′R*)-1′′-(3-Phenylpropyl)decahydroquinolin-3′′-yl)methyl
2-(3′-methyl-2′,5′-
dioxopyrrolidin-1′-yl)benzoate 11b. Using general method E anthranilate ester 10b (0.180 g, 0.360 mmol) gave
title compound 11b (0.172 g, 95%) as a green oil. RF = 0.7 (4:1 ethyl acetate, n-hexanes,); νmax/cm-1 2928, 2853,
1711, 1602, 1493, 1389, 1184, 1031; δH (400 MHz; CDCl3) 1.02-1.98 (1H, m, HA-7″), 1.23-1.52 (9H, m, H-4″,
16

H-6″, H-8″, 3ʹ-CH3), 1.57-1.62 (2H, m, H-5″), 1.72-1.80 (1H, m, HB-7″), 1.81-1.92 (2H, m, NCH2CH2CH2Ph),
ACCEPTED MANUSCRIPT
2.02-2.07 (1H, m, H-4a″), 2.14-2.20 (2H, m, HA-2″, H-3′), 2.47-2.59 (3H, m, HA-4′, NCH2CH2CH2Ph), 2.61-
2.65 (2H, m, NCH2CH2CH2Ph), 2.71-2.80 (1H, m, HB-2″), 2.82-2.93 (1H, m, H-8a″), 2.95-3.14 (2H, m, H-3′,
HB-4′), 4.06-4.13 (2H, m, CH2O), 7.14-7.28 (6H, m, H-6, Ar-H), 7.50 (1H, dt, J = 1.2, 7.7 Hz, H-5), 7.64 (1H,
*
dt, J = 1.2, 7.7 Hz, H-4), 8.07 (1H, d, J = 7.7 Hz, H-3); δC (100 MHz; CDCl3) 16.2 (3ʹ-CH3), 16.4 (3′-CH3 ),
17.0 (C-8″), 20.9 (C-6″), 25.3 (C-7″), 27.0 (C-4″), 28.7 (NCH2CH2CH2Ph), 31.3 (C-5″), 33.4
(NCH2CH2CH2Ph), 34.6 (C-4a″), 35.0 (C-3′), 35.2 (C-3′), 35.7 (C-3″), 36.8 (C-4′), 48.9 (C-2″), 53.2
(NCH2CH2CH2Ph), 58.4 (C-8a″), 67.9 (CH2O), 125.6 (Ar-CH), 127.2 (C-1), 128.1 (Ar-CH), 128.2 (Ar-CH),
129.2 (C-5), 129.7 (C-6), 131.3 (C-3), 132.6 (C-2), 133.2 (C-4), 141.9 (Ar-C), 164.2 (COO), 175.8 (C-2ʹ), 179.7
(C-5ʹ); HRMS (EI+) m/z = [M]+ C31H38N2O4 requires 502.28316; found 502.28394.
4.6.3
((3′′S,4a′′R,8a′′R)-1′′-((R)-1-Phenylethyl)decahydroquinolin-3′′-yl)methyl
2-(3′-methyl-2′,5′-
dioxopyrrolidin-1′-yl)benzoate 11c. Using general method E anthranilate ester 10c (0.100 g, 0.205 mmol) gave
20
title compound 11c (0.095 g, 95%) as a yellow oil. [α]D +30 (c 1.0, CHCl3); RF = 0.5 (4:1 ethyl acetate, n-
hexanes,); νmax/cm-1 2927, 2840, 1720, 1605, 1494, 1452, 1393, 1245, 1205, 1110, 1108; δH (400 MHz; CDCl3)
1.01-1.13 (1H, m, HA-7″), 1.17-1.33 (5H, m, H-6″, NCH(CH3)Ph), 1.35-1.46 (5H, m, H-4″, 3′-CH3), 1.51-1.71
(4H, m, H-5″, H-8″), 1.75-1.83 (1H, m, HB-7″), 1.89-1.92 (1H, m, H-3″), 1.95-2.10 (2H, m, HA-2″, H-4a″),
2.44-2.50 (2H, m, H-4′), 2.55 (1H, d, J = 8.8 Hz, HB-2), 2.95-3.14 (1H, m, H-3′), 3.18-3.21 (1H, m, H-8a″),
3.57-3.68 (1H, q, J = 6.8 Hz, NCH(CH3)Ph), 3.83-3.90 (1H, m, CHAHBO), 4.00-4.07 (1H, m, CHAHBO), 7.19-
1.40 (7H, m, H-5, H-6, Ar-H), 7.58-7.62 (2H, m, H-3, H-4); δC (100 MHz; CDCl3) 16.2 (3′-CH3), 16.4 (3′-
*
CH3 ), 17.3 (C-8″), 21.0 (NCH(CH3)Ph), 21.1 (C-6″), 25.5 (C-7″), 27.3 (C-4″), 30.8 (C-5″), 35.1 (C-3″), 35.3
(C-4a″), 36.3 (C-3′), 36.9 (C-4′), 48.8 (C-2″), 55.3 (NCH(CH3)Ph), 60.5 (C-8a″), 67.9 (CH2O), 126.4 (Ar-CH),
127.0 (C-1), 128.2 (2 × Ar-CH), 129.2 (C-5), 129.6 (C-6), 131.3 (C-3), 132.6 (C-2), 133.1 (C-4), 147.0 (Ar-C),
163.9 (COO), 171.0 (C-2ʹ), 179.8 (C-5ʹ); HRMS (EI+) m/z = [M]+ C30H36N2O4 requires 488.2675; found
488.2677.
4.6.4
((3′′S*,4a′′R*,9a′′R*)-1′′-Benzyldecahydro-1H-cyclohepta[b]pyridin-3′′-yl)methyl
2-(3′-methyl-2′,5′-
dioxopyrrolidin-1′-yl)benzoate 11d. Using general method E anthranilate ester 10d (0.130 g, 0.27 mmol) gave
title compound 11d (0.128 g, 97%) as a tan oil. RF = 0.8 (4:1 ethyl acetate, n-hexanes,); νmax/cm-1 2975, 2918,
1712, 1495, 1389, 1262, 1180, 1080; δH (400 MHz; CDCl3) 0.96-1.05 (1H, m, HA-5ʹʹ) 1.21 (1H, m, HA-8ʹʹ),
1.33-1.41 (1H, m, HA-9ʹʹ), 1.46-1.51 (3H, m, 3ʹ-CH3), 1.51-1.65 (3H, m, HB-8ʹʹ and H-6ʹʹor H-7ʹʹ), 1.66-1.73
(1H, m, HB-9ʹʹ), 1.74-1.84 (4H, m, H-4ʹʹ and H-6ʹʹ or H-7ʹʹ), 1.88-1.98 (1H, m, HB-5ʹʹ), 2.02-2.19 (3H, m, H-4ʹ,
HA-2ʹʹ), 2.45-2.60 (2H, m, H-3ʹ, HB-2ʹʹ), 2.80-2.87 (1H, m, H-9aʹʹ), 3.00-3.15 (2H, m, H-3ʹʹ, H-4aʹʹ), 3.60 (2H, s,
NCH2Ph), 3.96-4.10 (2H, m, OCH2), 7.20-7.39 (6H, m, H-6, Ar-H), 7.45 (1H, t, J = 7.5 Hz, H-5), 7.62 (1H, dt, J
*
= 1.0, 7.5 Hz, H-4), 7.90-7.97 (1H, m, H-3); δC (100 MHz, CDCl3) 16.3 (3ʹ-CH3), 16.4 (3ʹ-CH3 ), 20.0 (C-9ʹʹ),
23.4 (C-8ʹʹ), 28.1 (C-4ʹʹ), 31.2, 31.5 (C-6ʹʹ, C-7ʹʹ), 33.8 (C-5ʹʹ), 35.2 (C-4aʹʹ), 36.1 (C-3ʹʹ), 37.0 (C-4ʹ), 37.1 (C-
3ʹ), 49.2 (C-2ʹʹ), 58.9 (NCH2Ph), 62.4 (C-9aʹʹ), 68.1 (OCH2), 126.8 (Ar-CH), 127.3 (C-1) 128.2 (Ar-CH), 128.7
(Ar-CH), 129.4 (C-5), 129.8 (C-6), 131.5 (C-3), 132.6 (C-2), 133.3 (C-4), 139.5 (Ar-C), 164.2 (COO), 175.8 (C-
2ʹ), 176.0 (C-5ʹ); HRMS (EI+) m/z = [MH]+ C30H37N2O4 requires 489.2748; found 489.2739.
4.6.5 ((3′′S*,4a′′R*,9a′′R*)-1′′-(3-Phenylpropyl)decahydro-1H-cyclohepta[b]pyridin-3′′-yl)methyl 2-(3′-methyl-
2′,5′-dioxopyrrolidin-1′-yl)benzoate 11e. Using general method E anthranilate ester 10e (0.130 g, 0.25 mmol)
gave title compound 11e (0.128 g, 98%) as a tan oil. RF = 0.4 (1:1 ethyl acetate, n-hexanes,); νmax/cm-1 2926,
2851, 1711, 1494, 1372, 1183, 1044; δH (400 MHz; CDCl3) 0.93-1.06 (1H, m, HA-5ʹʹ), 1.09-1.39 (6H, m, H-4ʹʹ,
HA-8ʹʹ, HA-9ʹʹ and H-6ʹʹ or H-7ʹʹ), 1.39-1.51 (3H, m, 3ʹ-CH3), 1.51-1.64 (4H, m, HB-8ʹʹ, HB-9ʹʹ and H-6ʹʹ or H-
7ʹʹ), 1.72-1.85 (2H, m, NCH2CH2CH2Ph), 1.88-2.11 (3H, m, HA-2ʹʹ, H-3ʹʹ, HB-5ʹʹ), 2.42-2.68 (7H, m, HB-2ʹʹ, H-
4ʹ, NCH2CH2CH2Ph, NCH2CH2CH2Ph), 2.81-2.89 (1H, m, H-9aʹʹ), 2.97-3.16 (2H, m, H-3ʹ, H-4aʹʹ), 3.95-4.09
(2H, m, CH2O), 7.11-7.31 (6H, m, H-6, Ar-H), 7.50 (1H, td, J = 1.3, 7.7 Hz, H-5), 7.65 (1H, td, J = 1.3, 7.7 Hz,
*
H-4), 8.08 (1H, bd, J = 7.7 Hz, H-3); δC (100 MHz, CDCl3) 16.3 (3ʹ-CH3), 16.5 (3ʹ-CH3 ), 19.1 (C-9ʹʹ), 23.3 (C-
8ʹʹ), 24.5 (C-4ʹʹ), 28.2 (NCH2CH2CH2Ph), 31.1, 31.5 (C-6ʹʹ, C-7ʹʹ), 33.6 (C-5ʹʹ, NCH2CH2CH2Ph), 35.2 (C-3ʹ),
35.5 (C-3ʹ), 36.0 (C-4aʹʹ), 36.9 (C-4ʹ), 37.0 (C-3ʹʹ), 49.9 (C-2ʹʹ), 53.9 (NCH2CH2CH2Ph), 61.8 (C-9aʹʹ), 68.1
(CH2O), 125.6 (Ar-CH), 127.3 (Ar-CH), 127.3 (C-1), 128.1 (C-5, Ar-CH), 129.3 (C-6), 129.8 (C-3), 131.3 (C-
2), 133.3 (C-4), 142.4 (Ar-C), 171.1 (COO), 175.8 (C-2ʹ), 175.9 (C-5ʹ); HRMS (EI+) m/z = [MH]+ C32H41N2O4
requires 517.3061; found 517.3053.
17

4.6.6 ((3′′S,4a′′R,9a′′R)-1′′-((R)-1-Phenylethyl)decahydro-1H-cyclohepta[b]pyridin-3′′-yl)methyl 2-(3′-methyl-
2′,5′-dioxopyrrolidin-1′-yl)benzoate A11Cf. CUEsinPgTgEenDeraMl mAeNthoUd SECaRnthIPraTnilate ester 10f (0.09 g, 0.18 mmol)
20
gave title compound 11f (0.089 g, 99%) as a tan oil. [α]D +25 (c 1.0, CHCl3); RF = 0.35 (1:1 ethyl acetate, n-
hexanes,); νmax/cm-1 2917, 1708, 1452, 1389, 1179, 1079; δH (400 MHz; CDCl3) 0.98-1.04 (2H, m, HA-5ʹʹ and
HA-6ʹʹ or HA-7ʹʹ), 1.25-1.32 (3H, m, NCH(CH3)Ph), 1.35-1.48 (4H, m, 3ʹ-CH3, HA-8ʹʹ), 1.53-1.69 (4H, m, HB-8ʹʹ,
H-9ʹʹ and HB-6ʹʹor HB-7ʹʹ), 1.79-2.14 (7H, m, HA-2ʹʹ, H-4aʹʹ, H-4ʹʹ, HB-5ʹʹ and H-6ʹʹ or H-7ʹʹ), 2.43-2.58 (3H, m,
H-4ʹ, HB-2ʹʹ), 2.95-3.12 (2H, m, H-3ʹ, H-3ʹʹ), 3.22-3.28 (1H, m, NCH(CH3)Ph), 3.56-3.64 (1H, m, H-9aʹʹ), 3.75-
3.84 (1H, m, CHAHBO), 3.93-4.02 (1H, m, CHAHBO), 7.14-7.41 (6H, m, H-6, Ar-H), 7.54-7.64 (3H, m, H-3, H-
*
4, H-5); δC (100 MHz, CDCl3) 16.3 (3ʹ-CH3), 16.4 (3ʹ-CH3 ), 19.6 (C-9ʹʹ), 22.1 (NCH(CH3)Ph), 23.5 (C-8ʹʹ),
27.9 (C-4ʹʹ), 31.4, 31.8 (C-6ʹʹ, C-7ʹʹ), 34.2 (C-5ʹʹ), 35.2 (C-3ʹ), 35.4 (C-3ʹ), 36.2 (C-4aʹʹ), 37.0 (C-4ʹ), 37.3 (C-3ʹʹ),
48.1 (C-2ʹʹ), 57.9 (NCH(CH3)Ph), 61.3 (C-9aʹʹ), 67.9 (CH2O), 126.5 (Ar-CH), 127.2 (Ar-CH), 127.5 (Ar-CH),
128.3 (Ar-CH), 129.3 (C-5), 129.6 (C-6), 131.4 (C-3), 132.6 (C-2), 133.0 (C-4), 146.7 (Ar-C), 164.0 (COO),
175.7 (C-2ʹ), 175.9 (C-5ʹ); HRMS (EI+) m/z = [MH]+ C31H39N2O4 requires 503.2904; found 503.2913.
4.6.7
((3′′S*,4a′′S*,8a′′R*)-1′′-Benzyl-5′′,7′′-dimethyldecahydroquinolin-3′′-yl)methyl
2-(3′-methyl-2′,5′-
dioxopyrrolidin-1′-yl)benzoate 11g. Using general method E anthranilate ester 10g (0.07 g, 0.14 mmol) gave
title compound 11g (0.068 g, 97%) as a pale brown oil. RF = 0.2 (1:1 ethyl acetate, n-hexanes,); νmax/cm-1 2920,
1714, 1495, 1453, 1262, 1197, 1083; δH (400 MHz; CDCl3) 0.67-0.75 (1H, m, HA-6ʹʹ), 0.82 (3H, d, J = 6.6 Hz,
5ʹʹ-CH3), 0.86 (3H, d, J = 6.6 Hz, 7ʹʹ-CH3), 1.00-1.13 (2H, m, HA-4ʹʹ, HA-8ʹʹ), 1.25-1.31 (1H, m, H-3ʹʹ), 1.38-1.50
(3H, m, 3ʹ-CH3), 1.55-1.62 (1H, m, HA-2ʹʹ), 1.71-1.78 (1H, m, HB-6ʹʹ), 1.86-2.00 (2H, m, HB-4ʹʹ and H-5ʹʹ), 2.08-
2.23 (3H, m, H-4aʹʹ, H-7ʹʹ, HB-8ʹʹ), 2.32-2.37 (1H, m, H-8aʹʹ), 2.43-2.56 (2H, m, H-4ʹ), 2.88-3.11 (3H, m, HB-2ʹʹ,
H-3ʹ, NCHAHBPh), 3.78-4.00 (2H, m, CH2O), 4.09-4.16 (1H, m, NCHAHBPh), 7.16-7.35 (6H, m, H-6, Ar-CH),
7.39 (1H, bt, J = 7.6 Hz, H-5), 7.60 (1H, bt, J = 7.6 Hz, H-4), 7.75 (1H, bd, J = 7.6 Hz, H-3); δC (100 MHz,
CDCl3) 16.1 (3ʹ-CH3), 16.4 (3ʹ-CH3*), 19.6 (7ʹʹ-CH3), 22.1 (5ʹʹ-CH3), 26.1 (C-5ʹʹ), 28.8 (C-7ʹʹ), 30.2 (C-4ʹʹ), 31.0
(C-4aʹʹ), 35.1 (C-3ʹ), 35.2 (C-3ʹ), 36.8 (C-4ʹ), 38.6 (C-8ʹʹ), 43.7 (C-3ʹʹ), 45.1 (C-6ʹʹ), 56.8 (C-2ʹʹ, NCH2Ph), 62.1
(C-8aʹʹ), 68.2 (CH2O), 126.5 (Ar-CH), 127.2 (C-1), 128.1 (Ar-CH), 128.7 (Ar-CH), 129.2 (C-5), 129.6 (C-3),
131.2 (C-6), 132.7 (C-2), 133.1 (C-4), 140.0 (Ar-C), 164.4 (COO), 170.0 (CO), 171.0 (CO); HRMS (EI+) m/z =
[MH]+ C31H39N2O4 requires 503.2904; found 503.2914.
4.6.8 ((3′′S*,4a′′S*,8a′′R*)-5′′,7′′-Dimethyl-1′′-(3-phenylpropyl)decahydroquinolin-3′′-yl)methyl 2-(3′-methyl-
2′,5′-dioxopyrrolidin-1′-yl)benzoate 11h. Using general method E anthranilate ester 10h (0.08 g, 0.15 mmol)
gave title compound 11h (0.078 g, 98%) as a pale green oil. RF = 0.6 (2:1 ethyl acetate, n-hexanes,); νmax/cm-1
2926, 2864, 1710, 1453, 1390, 1259, 1182; δH (400 MHz; CDCl3) 0.64 (1H, q, J = 12.5 Hz, HA-6ʹʹ), 0.78 (3H, d,
J = 6.5 Hz, 5ʹʹ-CH3), 0.83 (3H, d, J = 6.5 Hz, 7ʹʹ-CH3), 0.87-0.94 (1H, m, HA-8ʹʹ), 1.02 (1H, td, J = 4.6, 13.0 Hz,
NCH2CHAHBCH2Ph), 1.16-1.24 (1H, m, H-3ʹʹ), 1.42-1.52 (3H, m, 3ʹ-CH3), 1.61-2.05 (8H, m, H-4ʹʹ, H-5ʹʹ, HB-
6ʹʹ, H-7ʹʹ, HB-8ʹʹ, NCH2CHAHBCH2Ph, NCHAHBCH2CH2Ph), 2.12-2.21 (1H, m, H-4aʹʹ), 2.28-2.34 (1H, m, H-
8aʹʹ), 2.41-2.72 (4H, m, H-2ʹʹ, NCH2CH2CH2Ph), 3.00-3.15 (4H, m, H-3ʹ, H-4ʹ, NCHAHBCH2CH2Ph), 3.91-4.08
(2H, m, CH2O), 7.14-7.32 (6H, m, H-6, Ar-CH), 7.49 (1H, td, J = 1.2, 7.7 Hz, H-5), 7.65 (1H, td, J = 1.2, 7.7
Hz, H-4), 8.09 (1H, d, J = 7.7 Hz, H-3); δC (100 MHz, CDCl3) 16.3 (3ʹ-CH3), 16.6 (3ʹ-CH3*), 19.8 (7ʹʹ-CH3),
22.6 (5ʹʹ-CH3), 26.0 (C-4ʹʹ), 26.5 (C-5ʹʹ), 28.8 (C-7ʹʹ), 30.2 (NCH2CH2CH2Ph), 31.4 (C-4aʹʹ), 33.8
(NCH2CH2CH2Ph), 35.1 (C-3ʹ), 35.3 (C-3ʹ), 37.0 (C-4ʹ), 38.3 (C-8ʹʹ), 43.5 (C-3ʹʹ), 45.1 (C-6ʹʹ), 52.3 (C-2ʹʹ), 57.0
(NCH2CH2CH2Ph), 60.3 (C-8aʹʹ), 68.6 (CH2O), 125.6 (Ar-CH), 127.6 (C-1), 128.2 (Ar-CH), 128.3 (Ar-CH),
129.3 (CH C-5), 129.8 (C-6), 131.4 (C-3), 132.8 (C-2), 133.3 (C-4), 142.3 (Ar-C), 164.5 (COO), 176.0 (C-2ʹ),
179.8 (C-5ʹ); HRMS (EI+) m/z = [MH]+ C33H43N2O4 requires 531.3217; found 531.3218.
4.7 Synthesis of succinimido anthranilate 16
4.7.1 (3S,4aR,8aR)-Ethyl 1-acetyldecahydroquinoline-3-carboxylate 13. To a solution of decahydroquinoline 7c
(0.342 g, 1.09 mmol) in methanol (5.0 mL) was added 10% palladium on carbon (0.035 g, 0.11 mmol) and the
resulting mixture was stirred under hydrogen (1 atm) for 18 h. The mixture was filtered through Celite which
was washed with ethyl acetate (25 mL) and the volatile solvent were removed in vacuo to give (3S,4aR,8aR)-
ethyl decahydroquinoline-3-carboxylate 12 (0.208 g, 91%) as a pale green oil which was used immediately
without further purification. To a solution of (3S,4aR,8aR)-ethyl decahydroquinoline-3-carboxylate 12 (0.200 g,
0.98 mmol) in dichloromethane (7.0 mL) was added freshly distilled triethylamine (7.0 mL) and the stirred
mixture was cooled to 0 °C, DMAP (0.009 g, 0.01 mmol) was added followed by acetic anhydride (0.102 mL,
1.08 mmol) and the mixture was allowed to warm to room temperature and stirred for 20 h. The resultant
18

mixture was acidified with 2M HCl (40 mL) and the organic layer was separated and the aqueous layer was
ACCEPTED MANUSCRIPT
washed with CH2Cl2 (2 × 40 mL). The combined organic extracts were washed with brine (80 mL), dried
(Na2SO4) and the volatile solvents were removed in vacuo to give the title compound 13 (0.250 g, quant.) as a
20
pale orange oil which was used without further purification. [α]D +10 (c 1.0, CHCl3); RF = 0.15 (1:1 ethyl
acetate, n-hexanes,); νmax/cm-1 2963, 2874, 1714 , 1652, 1363, 1182, 1102; δH (400 MHz; CDCl3) [* denotes
signal from minor rotamer] 1.18-1.35 (7H, m, OCH2CH3, H-5, H-7), 1.36-1.47 (4H, m, H-5*, H-6), 1.57-1.68
(6H, m, H-6*, H-8, H-8*), 1.68-1.76 (4H, m, H-4, H-4*), 1.77-1.85 (3H, m, H-4a, H-7*), 1.86-1.94 (3H, m, H-
4*, H-4a*), 2.06 (6H, d, J = 4.1 Hz, COCH3, COCH3*), 2.35-2.46 (2H, m, H-2), 2.62 (1H, t, J = 12.4 Hz, HA-
2*), 3.06 (1H, q, J = 7.0 Hz, HB-2*), 3.14 (1H, t, J = 12.4 Hz, H-3), 3.65 (1H, d, J = 12.0 Hz, H-8a), 3.73 (1H,
dd, J = 3.8, 12.4 Hz, H-3*), 4.05-4.16 (4H, m, OCH2CH3, OCH2CH3*), 4.55-4.63 (1H, m, H-8a*), 4.66-4.73
(1H, m, HB-2*); δC (100 MHz; CDCl3) 8.5 (OCH2CH3), 14.1 (OCH2CH3*), 19.7 (C-5), 20.0 (C-5*), 21.5
(COCH3), 22.1 (COCH3*), 23.4 (C-6), 24.5 (C-6*), 25.3 (C-7), 25.5 (C-7*), 27.2 (C-4), 27.3 (C-4*), 30.7 (C-8),
30.9 (C-8*), 33.8 (C-4a), 34.8 (C-4a*), 37.2 (C-2), 42.6 (C-2*), 41.9 (C-3), 42.7 (C-3*), 45.6 (C-8a), 49.5 (C-
8a*), 60.5 (OCH2CH3), 60.7 (OCH2CH3*), 168.9(NCO), 169.1 (NCO*), 173.1 (COO), 173.3 (COO*); HRMS
(EI+) m/z = [MH]+ C14H24NO3 requires 254.1751; found 254.1746.
4.7.2 ((3S,4aR,8aR)-1-Ethyldecahydroquinolin-3-yl)methanol 14. To a solution of lithium aluminium hydride
(0.187 g, 4.9 mmol) in THF (15.0 mL) at 0 °C was added acetamide 13 (0.240 g, 0.98 mmol) in THF (15.0 mL)
in a dropwise manner. The resulting mixture heated at reflux, under nitrogen, for 23 h. The resulting mixture
was allowed to cool to room temperature and was quenched by the dropwise addition of water (1.5 mL). The
mixture was filtered through Celite and washed with ethyl acetate (20.0 mL) and the volatile solvents were
removed in vacuo to give the title compound 14 (0.190 g, quant.) as a pale orange solid which was used without
further purification. [α]D20 +11 (c 1.0, CHCl3); m.p. 90-92 °C; RF = 0.25 (4:1 ethyl acetate, n-hexanes,); νmax/cm-
1 3316, 2950, 1469, 1373, 1080, 1044, 769; δH (400 MHz; CDCl3) 1.07 (3H, t, J = 7.3 Hz, NCH2CH3), 1.10-1.18
(1H, m, HA-7), 1.29-1.41 (4H, m, H-5, H-8), 1.42-1.52 (2H, m, H-6), 1.53-1.60 (2H, m, H-4), 1.72-1.78 (1H, m,
HB-7), 1.83-1.94 (1H, m, H-3), 1.96-2.03 (1H, m, H-4a), 2.07 (1H, t, J = 11.5 Hz, HA-2), 2.48-2.59 (2H, m,
NCH2CH3), 2.71 (1H, dd, J = 11.5, 3.9 Hz, HB-2), 2.78-2.85 (1H, m, H-8a), 3.42-3.55 (2H, m, CH2OH); δC (100
MHz; CDCl3) 12.9 (NCH2CH3), 16.7 (C-6), 21.0 (C-5), 25.6 (C-7), 27.2 (C-8), 32.0 (C-4), 35.2 (C-4a), 39.3 (C-
3), 47.9 (NCH2CH3), 49.1 (C-2), 58.2 (C-8a), 66.7 (CH2OH); HRMS (EI+) m/z = [MH]+ C12H24NO requires
198.1851; found 198.1852.
4.7.3 ((3′′S,4a′′R,8a′′R)-1′′-Ethyldecahydroquinolin-3′′-yl)methyl 2-(3′-methyl-2′,5′-dioxo-2′,5′-dihydro-1H-
pyrrol-1′-yl)benzoate 15. To a solution of alcohol 14 (0.052 g, 0.26 mmol) in dry dichloromethane (5.0 mL) was
added 2-(3-methyl-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoic acid 9 (0.120 g, 0.52 mmol), DMAP (3.0 mg,
0.03 mmol) and DCC (0.107 g, 0.52 mmol) and the mixture was stirred for 18 h. The mixture was filtered
through Celite and washed with ethyl acetate (30 mL). The filtered mixture was washed with aqueous NaHCO3
(2 × 30 mL), dried (Na2SO4) and the volatile solvents were removed in vacuo to give the title compound 15
(0.087 g, 80%) as a green oil which was used without further purification. [α]D20 +7 (c 1.0, CHCl3); RF = 0.8 (4:1
ethyl acetate, n-hexanes,); νmax/cm-1 2928, 2854, 1712, 1453, 1393, 1258, 1108; δH (400 MHz; CDCl3) 1.08 (3H,
t, J = 7.2 Hz, NCH2CH3), 1.11-1.21 (1H, m, HA-7ʹʹ), 1.23-1.37 (4H, m, H-5ʹʹ, H-8ʹʹ), 1.39-1.47 (2H, m, H-6ʹʹ),
1.52-1.61 (3H, m, H-4ʹʹ, HB-7ʹʹ), 1.94-2.01 (1H, m, H-4aʹʹ), 2.05-2.11 (2H, m, HA-2ʹʹ, H-3ʹʹ), 2.16 (3H, s, 3ʹ-
CH3), 2.45-2.60 (2H, m, NCH2CH3), 2.67 (1H, d, J = 8.6 Hz, HB-2ʹʹ), 2.79-2.89 (1H, m, H-8aʹʹ), 4.01-4.14 (2H,
m, CH2O), 6.50 (1H, s, H-4ʹ), 7.29 (1H, d, J = 7.4 Hz, H-6), 7.49 (1H, t, J = 7.4 Hz, H-5), 7.63 (1H, t, J = 7.4
Hz, H-4), 8.08 (1H, d, J = 7.4 Hz, H-3); δC (100 MHz; CDCl3) 11.0 (3ʹ-CH3), 12.8 (NCH2CH3), 16.6 (C-6ʹʹ),
20.8 (C-5ʹʹ), 25.3 (C-7ʹʹ), 27.3 (C-8ʹʹ), 31.5 (C-4ʹʹ), 35.1 (C-4aʹʹ), 36.0 (C-3ʹʹ), 47.7 (NCH2CH3), 48.8 (C-2ʹʹ),
57.9 (C-8aʹʹ), 68.3 (CH2O), 127.5 (C-4ʹ), 127.8 (C-1), 128.8 (C-5), 130.2 (C-6), 131.4 (C-3), 131.6 (C-2), 133.0
(C-4), 146.1 (C-3ʹ), 164.7 (COO), 169.5 (C-2ʹ), 170.6 (C-5ʹ); HRMS (EI+) m/z = [MH]+ C24H31N2O4 requires
411.2278; found 411.2287.
4.7.4
((3′′S,4a′′R,8a′′R)-1′′-Ethyldecahydroquinolin-3′′-yl)methyl
2-(3′-methyl-2′,5′-dioxopyrrolidin-1′-
yl)benzoate 16. To a solution of maleimide 15 (0.08 g, 0.19 mmol) in ethyl acetate (2.0 mL) was added 10%
palladium on carbon (9.0 mg) and the resulting solution was stirred under hydrogen (1 atm) for 18 h. The
mixture was filtered through Celite which was washed with ethyl acetate (20 mL) and the volatile solvents were
removed in vacuo to give the title compound 16 (0.079 g, 99%) as a pale brown oil. [α]D20 +5 (c 1.0, CHCl3); RF
= 0.75 (4:1 ethyl acetate, n-hexanes,); νmax/cm-1 2927, 2840, 1711, 1491, 1380, 1110, 1108; δH (400 MHz;
19

CDCl3) 1.00 (3H, t, J = 7.0 Hz, NCH2CH3), 1.19-1.26 (1H, m, HA-7ʹʹ), 1.28-1.43 (7H, m, 3ʹ-CH3, H-5ʹʹ, H-8ʹʹ),
ACCEPTED MANUSCRIPT
1.46-1.53 (2H, m, H-4ʹʹ), 1.63-1.73 (1H, m, HB-7ʹʹ), 1.90-1.98 (1H, m, H-4aʹʹ), 2.03-2.09 (2H, m, HA-2ʹʹ, H-3ʹʹ),
2.38-2.53 (4H, m, H-4ʹ, NCH2CH3), 2.63 (1H, d, J = 7.0 Hz, HB-2ʹʹ), 2.73-2.80 (1H, m, H-8aʹʹ), 2.91-3.06 (1H,
m, H-3ʹ), 3.95-4.07 (2H, m, CH2O), 7.13-7.23 (1H, m, H-6), 7.43 (1H, t, J = 7.0 Hz, H-5), 7.56 (1H, t, J = 7.0
*
Hz, H-4), 8.02 (1H, d, J = 7.0 Hz, H-3); δC (100 MHz; CDCl3) 12.9 (NCH2CH3), 16.2 (3ʹ-CH3), 16.6 (3ʹ-CH3 ),
16.7 (C-6ʹʹ), 20.8 (C-5ʹʹ), 25.3 (C-7ʹʹ), 27.3 (C-8ʹʹ), 31.5 (C-4ʹʹ), 35.1 (C-3ʹ, C-4aʹʹ), 36.1 (C-3ʹʹ), 36.9 (C-4ʹ), 47.7
(NCH2CH3), 48.8 (C-2ʹʹ), 57.9 (C-8aʹʹ), 68.2 (CH2O), 127.3 (C-1), 129.2 (C-5), 129.7 (C-6), 131.3 (C-2), 132.6
(C-3), 133.2 (C-4), 164.1 (COO), 171.0 (C-2ʹ), 175.6 (C-5ʹ); HRMS (EI+) m/z = [MH]+ C24H33N2O4 requires
413.2435; found 413.2436.
Acknowledgements
We are grateful for the financial support from The University of Auckland for a Doctoral Scholarship (ED).
References
1. (a) Manske, R. H. Can. J. Res. 1938, 16B, 57. (b) Goodson, J. A. J. Chem. Soc. 1943, 139-141.
2. (a) Jennings, K. R.; Brown, D. G.; Wright, D. P. Experientia 1986, 42, 611-613. (b) Kukel, C. F.; Jennings,
K. R. Can. J. Physiol. Pharmacol. 1994, 72, 104-107. (c) Macallan, D. R. E.; Lunt, G. G.; Wonnacott, S.;
Swanson, K. L.; Rapoport, H.; Albuquerque, E. X. FEBS Lett. 1988, 226, 357-363. (d) Reina, M.; González-
Coloma, A. Phytochem. Rev. 2007, 6, 81-95.
3. Wonnacott, S.; Alburquerque, E. X.; Bertrand, D. Methods Neurosci. 1993, 12, 263-275.
4. Alexander, J.; Bindra, D. S.; Glass, J. D.; Holahan, M. A.; Renyer, M. L.; Rork, G. S.; Sitko, G. R.; Stranieri,
M. T.; Stupienski, R. F.; Veerapanane, H.; Cook, J. J. J. Med. Chem. 1996, 39, 480-486.
5. Lloyd, G. K.; Williams, M. J. Pharm. Exp. Ther. 2000, 292, 461-467.
6. (a) Tsuneki, H.; You, Y.; Toyooka, N.; Kagawa, S.; Kobayashi, S.; Sasaoka, T.; Nemoto, H.; Kimura, I.;
Dani, J. A. Mol. Pharmacol. 2004, 66, 1061-1069; (b) Toyooka, N.; Tsuneki, H.; Kobayashi, S.; Zhou, D.;
Kawasaki, M.; Kimura, I.; Sasaoka, T.; Nemoto, H. Curr. Chem. Biol. 2007, 1, 97-114.
7. Jensen, A. A.; Frolund, B.; Liljefors, T.; Krogsgaard-Larsen, P. J. Med. Chem. 2005, 48, 4705-4745.
8. Manners, G. D.; Panter, K. E.; Pelleteir, S. W. J. Nat. Prod. 1995, 58, 863-869.
9. (a) McKay, D. B.; Chang, C.; Gonzalez-Cestari, T. F.; Mckay, S. B.; El-Hajj, R. A.; Bryant, D. L.; Zhu, M.
X.; Swaan, P. W.; Arason, K. M.; Pulipaka, A. B.; Orac, C. M.; Bergmeier, S. C. Mol. Pharmacol. 2007, 71,
1288-1297. (b) Bryant, D. L.; Free, R. B.; Thomasy, S. M.; Lapinsky, D. J.; Ismail, K. A.; McKay, S. B.;
Bergmeier, S. C.; McKay, D. B. Neurosci. Res. 2002, 42, 57-63. (b) Bergmeier, S. C.; Lapinsky, D. J.; Free, R.
B.; McKay, D. B. Bioorg. Med. Chem. Lett. 1999, 9, 2263-2266; (c) Bryant, D. L.; Free, R. B.; Thomasy, S. M.;
Lapinsky, D. J.; Ismail, K. A.; Arason, K. M.; Bergmeier, S. C.; McKay, D. B. Ann. N. Y. Acad. Sci. 2002, 971,
139-141; (e) Bergmeier, S. C.; Ismail, K. A.; Arason, K. M.; McKay, S.; Bryant, D. L.; McKay, D. B. Bioorg.
Med. Chem. Lett. 2004, 14, 3739-3742; (f) Ismail, K. A.; Bergmeier, S. C. Eur. J. Med. Chem. 2002, 37, 469-
474; (h) Huang, J.; Orac, C. M.; McKay, S.; McKay, D. B.; Bergmeier, S. C. Bioorg. Med. Chem. 2008, 16,
3816-3820.
10. (a) Barker, D.; McLeod, M. D.; Brimble, M. A.; Savage, G. P. Tetrahedron Lett. 2001, 42, 1785-1788; (b)
Sparrow, K. J.; Carley, S.; Sohnel, T.; Barker, D.; Brimble, M. A. Tetrahderon 2015, 71, 2210-2221. (c)
Goodall, K. J.; Brimble, M. A.; Barker, D. Tetrahedron 2012, 68, 5759-5778. (d) Sparrow, K. J.; Barker, D.;
Brimble, M. A. Tetrahedron 2012, 68, 1017-1028. (e) Sparrow, K. J.; Barker, D.; Brimble, M. A. Tetrahedron
2011, 67, 7989-7999. (f) Chan, Y.; Balle, J.; Sparrow, K. J.; Boyd, P. D. W.; Brimble, M. A.; Barker, D.
Tetrahedron 2010, 66, 7179-7191. (g) Chan, Y.; Guthmann, H.; Brimble, M. A.; Barker, D. Synlett 2008, 17,
2601-2604. (h) Goodall, K. J.; Brimble, M. A.; Barker, D. Magn. Reson. Chem. 2008, 46, 75-79. (i) Goodall, K.
20

J.; Brimble, M. A.; Barker, D. MagnA. RCesConE. CPhTemE.D200M7,A45N, 6U95S-6C9R9. I(jP) TGoodall, K. J.; Brimble, M. A.;
Barker, D. Magn. Reson. Chem. 2006, 44, 980-983. (k) Lehmann, A.; Brocke, C.; Barker, D.; Brimble, M. A.
Eur. J. Org. Chem.2006, 14, 3205-3215. (l) Barker, D.; Lin, D. H.-S.; Carland, J. E.; Chu, C. P.-Y.; Chebib, M.;
Brimble, M. A.; Savage, G. P.; McLeod, M. D. Bioorg. Med. Chem. 2005, 13, 4565-4575. (m) Barker, D.
Brimble, M. A.; McLeod, M. D. Tetrahedron 2004, 60, 5953-5963. (n) Barker, D.; Brimble, M. A.; McLeod, M.
D.; Savage, G. P. Org. Biomol. Chem. 2004, 2, 1659-1669. (o) Barker, D.; Brimble, M. A.; McLeod, M. D.;
Savage, G. P. Tetrahedron Lett. 2002, 43, 6019-6022. (p) Barker, D.; Brimble, M. A.; McLeod, M. D.; Savage,
G. P.; Wong, D. J. J. Chem. Soc., Perkin Trans. 1, 2002, 7, 924-931. (q) Goodall, K. J.; Barker, D.; Brimble, M.
A. Synlett 2005, 1809-1827.
11. (a) Doisy, X.; Blagbrough, I. S.; Wonnacott, S.; Potter, B. V. L. Pharm. Pharmacol. Commun. 1998, 4, 313-
317; (g) Simoni, D.; Rossi, M.; Rondanin, R.; Baruchello, R.; Grisolia, G.; Eleopra, M.; Giovannini, R.;
Bozzoli, A.; Davalli, S.; Di Fabio, R.; Donati, D. Tetrahedron Lett. 2005, 46, 759-762.
12. (a) Guthmann, H.; Conole, D.; Wright, E.; Koerber, K.; Barker, D.; Brimble, M. A. Eur. J. Org. Chem.
2009, 1944-1960. (b) Huang, J.; Bergmeier, S. C. Tetrahedron 2008, 64, 6434-6439.
13. (a) Horii, Z.; Watanabe, T.; Ikeda, M.; Kurihara, T.; Tamura, Y. Yakugaku Zasshi 1964, 84, 142–145. (b)
Cassady, J. M.; Li, G. S.; Spitzner, E. B.; Floss, H. G.; Clemens, J. A. J. Med. Chem. 1974, 17, 300-307.
14. Weijers, C. A. G. M.; Konst, P. M.; Franssen, M. C. R.; Sudholter, E. J. R. Org. Biomol. Chem. 2007, 5,
3106-3114.
15. (a) Villieras, J.; Rambaud, M. Org. Synth. 1988, 66, 220-224. (b) Byun, H.-S.; Reddy, K. C.; Bittman, R.
Tetrahedron Lett. 1994, 35, 1371-1374. (c) Hediger, M. E. Bioorg. Med. Chem. 2004, 12, 4995-5010.
16. Barker, D.; Brimble, M. A.; McLeod, M. D. Synthesis 2003, 656-658.
21